{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Imports"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [],
   "source": [
    "import sys\n",
    "import os\n",
    "script_dir = os.getcwd()\n",
    "root_dir = os.path.join(os.path.dirname(os.path.abspath(script_dir)))\n",
    "sys.path.append(os.path.join(os.path.dirname(os.path.abspath(script_dir))))\n",
    "\n",
    "import json\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "from utils.io import load_object, save_object\n",
    "from utils.evaluation import calc_eval_metrics\n",
    "from collections import Counter\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "import colorcet as cc\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Manuscript Figures"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 2A. Accuracy of LLM across various prompt strategies"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [],
   "source": [
    "moalmanac_data=pd.read_csv(os.path.join(root_dir, 'data/moa_fda_queries_answers.csv'), index_col=0)\n",
    "synthetic_prompt_groundtruth_dict=load_object(os.path.join(root_dir, 'data/synthetic_prompt_groundtruth_dict.pkl'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [],
   "source": [
    "llm_mistnemo_res_dict_0 = load_object(filename=os.path.join(root_dir, 'output/LLM_res_mistnemo/stra0n1temp0.0_res_dict.pkl'))\n",
    "llm_mistnemo_res_dict_1 = load_object(filename=os.path.join(root_dir, 'output/LLM_res_mistnemo/stra1n1temp0.0_res_dict.pkl'))\n",
    "llm_mistnemo_res_dict_2 = load_object(filename=os.path.join(root_dir, 'output/LLM_res_mistnemo/stra2n1temp0.0_res_dict.pkl'))\n",
    "llm_mistnemo_res_dict_3 = load_object(filename=os.path.join(root_dir, 'output/LLM_res_mistnemo/stra3n1temp0.0_res_dict.pkl'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                               0          1\n",
      "Basic_prompt            0.692308  69.230769\n",
      "Basic_prompt_condition  0.534188  53.418803\n",
      "Basic_prompt_system     0.645299  64.529915\n",
      "Basic_prompt_combined   0.512821  51.282051\n"
     ]
    }
   ],
   "source": [
    "plot_res = pd.DataFrame(\n",
    "    {\n",
    "    'Basic_prompt' : [calc_eval_metrics(llm_mistnemo_res_dict_0['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)['avg_partial_match_acc']],\n",
    "    'Basic_prompt_condition' : [calc_eval_metrics(llm_mistnemo_res_dict_1['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)['avg_partial_match_acc']],\n",
    "    'Basic_prompt_system' : [calc_eval_metrics(llm_mistnemo_res_dict_2['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)['avg_partial_match_acc']],\n",
    "    'Basic_prompt_combined' : [calc_eval_metrics(llm_mistnemo_res_dict_3['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)['avg_partial_match_acc']]\n",
    "    }\n",
    "    )\n",
    "    \n",
    "plot_res = plot_res.iloc[0,:].to_frame()\n",
    "plot_res[1] = plot_res[0]*100\n",
    "print(plot_res)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "plot_res[1].rename(index={\n",
    "    'Basic_prompt':'(1) Basic prompt',\n",
    "    'Basic_prompt_condition':'(2) Basic prompt + condition',\n",
    "    'Basic_prompt_system':'(3) Basic prompt + system role',\n",
    "    'Basic_prompt_combined':'(4) Basic prompt + (2) + (3)'\n",
    "                          }, inplace=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 350x300 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# set figure size\n",
    "plt.rcParams[\"figure.figsize\"] = [3.5, 3]\n",
    "\n",
    "# set color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# create bar plot\n",
    "ax=plot_res[1].plot(kind='bar', color=cols[3], width=0.6, legend=False)\n",
    "\n",
    "# add text\n",
    "for i, v in enumerate(plot_res[1]):\n",
    "    ax.text(x=i, y=v+0.05, s=f'{v:.2f}', ha='center', va='bottom', fontsize=10)\n",
    "\n",
    "# x, y label and ticks\n",
    "ax.set_xlabel('Prompt strategy', fontsize=11)\n",
    "ax.set_ylabel('Partial Match Accuracy (%)', fontsize=11)\n",
    "plt.xticks(rotation=45, ha='right')\n",
    "\n",
    "# borders\n",
    "ax.spines['top'].set_visible(False)\n",
    "ax.spines['right'].set_visible(False)\n",
    "\n",
    "# highlight first bar\n",
    "ax.patches[0].set_facecolor(cols[3])\n",
    "\n",
    "# set alpha for the rest of the bars\n",
    "for i, patch in enumerate(ax.patches):\n",
    "    if i != 0:  \n",
    "        patch.set_alpha(0.5) \n",
    "\n",
    "# save\n",
    "save = True\n",
    "if save == True:\n",
    "    plt.savefig('./figures/Figure2_accuracyLLMprompt.jpeg', dpi=500, bbox_inches='tight')\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 2B. Accuracy of LLMs of various sizes across prompt strategies"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Statistical test on basic vs. combination prompts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load McNemar package\n",
    "from statsmodels.stats.contingency_tables import mcnemar\n",
    "\n",
    "# Function to create a contingency matrix for McNemar's test\n",
    "def create_mcnemar_table(y_pred_A, y_pred_B):\n",
    "    \n",
    "    # Convert to numpy arrays for easy element-wise comparison\n",
    "    y_pred_A = np.array(y_pred_A)\n",
    "    y_pred_B = np.array(y_pred_B)\n",
    "\n",
    "    # Compute contingency table values\n",
    "    a = np.sum((y_pred_A == True) & (y_pred_B == True)) # Both correct\n",
    "    b = np.sum((y_pred_A == True) & (y_pred_B == False)) # A correct, B incorrect\n",
    "    c = np.sum((y_pred_A == False) & (y_pred_B == True)) # A incorrect, B correct\n",
    "    d = np.sum((y_pred_A == False) & (y_pred_B == False)) # Both incorrect\n",
    "\n",
    "    # Create contingency table\n",
    "    table = np.array([[a, b], [c, d]])\n",
    "\n",
    "    return({\n",
    "        'table':table,\n",
    "        'bc':b+c\n",
    "        })"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load LLM-only outputs and evaluate\n",
    "models = ['mist7B', 'mist8B', 'mistnemo', 'mistlarge', 'gptmini', 'gpt']\n",
    "strategies = [0, 3]\n",
    "\n",
    "llm_output_dicts = {}\n",
    "llm_eval_res = {}\n",
    "partial_acc_dicts = {}\n",
    "\n",
    "for model in models:\n",
    "    model_eval = {}\n",
    "    for strategy in strategies:\n",
    "        output_key = f\"llm_{model.lower()}_res_dict_{strategy}\"\n",
    "        eval_key = f\"llm_{model.lower()}_eval_res_{strategy}\"\n",
    "        \n",
    "        # Load LLM outputs\n",
    "        path = os.path.join(root_dir, f'output/LLM_res_{model}/stra{strategy}n1temp0.0_res_dict.pkl')\n",
    "        llm_output_dicts[output_key] = load_object(filename=path)\n",
    "        \n",
    "        # Evaluate LLM outputs\n",
    "        eval_result = calc_eval_metrics(llm_output_dicts[output_key]['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "        llm_eval_res[eval_key] = eval_result\n",
    "        \n",
    "        # Save each model's results\n",
    "        model_eval[strategy] = {'partial_match_acc':eval_result['partial_match_acc'], 'avg_partial_match_acc':eval_result['avg_partial_match_acc']}\n",
    "        \n",
    "    partial_acc_dicts[f\"{model}_partial_acc_dict\"] = model_eval\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create contingency table for mcnemar's test\n",
    "mcnemar_tables = {}\n",
    "for model in models:\n",
    "    mcnemar_tables[f'{model}_partial_table'] = create_mcnemar_table(\n",
    "        partial_acc_dicts[f'{model}_partial_acc_dict'][3]['partial_match_acc'], \n",
    "        partial_acc_dicts[f'{model}_partial_acc_dict'][0]['partial_match_acc']\n",
    "    )\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Perform McNemar's test (use exact=True if b+c < 25)\n",
    "def conduct_mcnemar_test(table):\n",
    "    if table['bc'] < 25:\n",
    "        result = mcnemar(table['table'], exact=True, correction=True) \n",
    "    else:\n",
    "        result = mcnemar(table['table'], exact=False, correction=True)\n",
    "        \n",
    "    return(result)\n",
    "\n",
    "# Print results\n",
    "def print_mcnemar_res(mcnemar_result, alpha):\n",
    "    significance = mcnemar_result.pvalue < alpha\n",
    "    print(f\"Significant: {significance}; Test Statistic: {mcnemar_result.statistic}; P-value: {mcnemar_result.pvalue}\")    \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Significant: False; Test Statistic: 2.938775510204082; P-value: 0.08647626549366548\n",
      "Significant: False; Test Statistic: 2.56; P-value: 0.10959858339911568\n",
      "Significant: True; Test Statistic: 38.20454545454545; P-value: 6.370385309896191e-10\n",
      "Significant: False; Test Statistic: 5.0; P-value: 0.30175781249999994\n",
      "Significant: False; Test Statistic: 5.0; P-value: 0.09625244140625\n",
      "Significant: False; Test Statistic: 3.0; P-value: 0.057373046875\n"
     ]
    }
   ],
   "source": [
    "# Run McNemar and get accuracies\n",
    "model_labels = dict(zip(models, ['mist_7B', 'mist_8B', 'mistnemo_12B', 'mistlarge_123B', 'gpt4omini', 'gpt4o']))\n",
    "\n",
    "mcnemar_result = {}\n",
    "accuracy = {}\n",
    "p_values = {}\n",
    "\n",
    "for model, label in model_labels.items():\n",
    "    # Run McNemar's test\n",
    "    mcnemar_result[f'{model}_mcnemar_res'] = conduct_mcnemar_test(mcnemar_tables[f'{model}_partial_table'])\n",
    "    print_mcnemar_res(mcnemar_result[f'{model}_mcnemar_res'], alpha=0.05)\n",
    "\n",
    "    # Get p-values\n",
    "    p_values[label] = mcnemar_result[f'{model}_mcnemar_res'].pvalue\n",
    "    \n",
    "    # Get accuracies\n",
    "    accuracy[label] = [\n",
    "        partial_acc_dicts[f'{model}_partial_acc_dict'][0]['avg_partial_match_acc'], \n",
    "        partial_acc_dicts[f'{model}_partial_acc_dict'][3]['avg_partial_match_acc']\n",
    "    ]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Plot bar graph"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "(1) Basic prompt",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "(2) Basic prompt + (2) + (3)",
         "rawType": "float64",
         "type": "float"
        }
       ],
       "ref": "c7a70ad3-4cd5-4160-ab34-2b287997f95c",
       "rows": [
        [
         "mist_7B",
         "32.05128205128205",
         "37.60683760683761"
        ],
        [
         "mist_8B",
         "44.44444444444444",
         "48.29059829059829"
        ],
        [
         "mistnemo_12B",
         "69.23076923076923",
         "51.28205128205128"
        ],
        [
         "mistlarge_123B",
         "67.09401709401709",
         "64.95726495726495"
        ],
        [
         "gpt4omini",
         "70.51282051282051",
         "67.09401709401709"
        ],
        [
         "gpt4o",
         "75.64102564102564",
         "72.22222222222221"
        ]
       ],
       "shape": {
        "columns": 2,
        "rows": 6
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>(1) Basic prompt</th>\n",
       "      <th>(2) Basic prompt + (2) + (3)</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>mist_7B</th>\n",
       "      <td>32.051282</td>\n",
       "      <td>37.606838</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mist_8B</th>\n",
       "      <td>44.444444</td>\n",
       "      <td>48.290598</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mistnemo_12B</th>\n",
       "      <td>69.230769</td>\n",
       "      <td>51.282051</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mistlarge_123B</th>\n",
       "      <td>67.094017</td>\n",
       "      <td>64.957265</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>gpt4omini</th>\n",
       "      <td>70.512821</td>\n",
       "      <td>67.094017</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>gpt4o</th>\n",
       "      <td>75.641026</td>\n",
       "      <td>72.222222</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                (1) Basic prompt  (2) Basic prompt + (2) + (3)\n",
       "mist_7B                32.051282                     37.606838\n",
       "mist_8B                44.444444                     48.290598\n",
       "mistnemo_12B           69.230769                     51.282051\n",
       "mistlarge_123B         67.094017                     64.957265\n",
       "gpt4omini              70.512821                     67.094017\n",
       "gpt4o                  75.641026                     72.222222"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_models_acc=pd.DataFrame(accuracy)\n",
    "all_models_acc.rename(index={\n",
    "    0:'(1) Basic prompt',\n",
    "    1:'(2) Basic prompt + (2) + (3)'\n",
    "    }, inplace=True\n",
    ")\n",
    "\n",
    "all_models_acc=all_models_acc*100\n",
    "all_models_acc=all_models_acc.transpose()\n",
    "all_models_acc"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "def pval_to_stars(p):\n",
    "    if p < 0.001:\n",
    "        return '***'\n",
    "    elif p < 0.01:\n",
    "        return '**'\n",
    "    elif p < 0.05:\n",
    "        return '*'\n",
    "    else:\n",
    "        return ''"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 500x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plot_res=all_models_acc\n",
    "\n",
    "# set figure size\n",
    "plt.rcParams[\"figure.figsize\"] = [5, 5]\n",
    "\n",
    "# set color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# create a mapping of rownames to colors\n",
    "row_colors = dict(zip(plot_res.columns, [cols[3],cols[25]]))\n",
    "\n",
    "# create bar plot\n",
    "ax=plot_res.plot(kind='barh', color=row_colors, width=0.6, legend=False)\n",
    "\n",
    "# add text\n",
    "for bar in ax.patches:\n",
    "    x = bar.get_width() # bar length (horizontal position)\n",
    "    y = bar.get_y() + bar.get_height()/2 # center the bar (vertical position)\n",
    "    ax.text(x+0.02, y, f'{x:.0f}', ha='left', va='center', fontsize=9)\n",
    "    \n",
    "# add p-value significance\n",
    "yticks = np.arange(len(plot_res.index))  \n",
    "bar_height = ax.patches[0].get_height()\n",
    "n_bars = plot_res.shape[1] # bars per group (i.e., columns in plot_res)\n",
    "bar_offsets = np.linspace(-bar_height/2, bar_height/2, n_bars, endpoint=False) # offsets per bar within group\n",
    "\n",
    "for i, (label, pval) in enumerate(p_values.items()):\n",
    "    if label not in plot_res.index:\n",
    "        continue\n",
    "    row_idx = plot_res.index.get_loc(label)\n",
    "\n",
    "    # Get the bars for this group\n",
    "    bar_group = ax.patches[row_idx * n_bars : (row_idx + 1) * n_bars]\n",
    "    if len(bar_group) < 2:\n",
    "        continue\n",
    "\n",
    "    bar1, bar2 = bar_group\n",
    "    y_pos = yticks[row_idx] + np.mean(bar_offsets[:2]) + bar_height / 2\n",
    "\n",
    "    # Place to the right of the longer bar\n",
    "    x_pos = max(bar1.get_width(), bar2.get_width()) + 1.0\n",
    "\n",
    "    # Convert p-value to stars\n",
    "    sig = pval_to_stars(pval)\n",
    "    if sig:\n",
    "        ax.text(x_pos, y_pos, sig,\n",
    "                ha='left', va='center',\n",
    "                fontsize=11, fontweight='bold', rotation=90)\n",
    "\n",
    "    \n",
    "# x, y label and ticks\n",
    "ax.set_xlabel('Partial Match Accuracy (%)', fontsize=12)\n",
    "ax.set_ylabel('')\n",
    "ax.tick_params(labelsize=11)\n",
    "for spine in ax.spines.values():\n",
    "    spine.set_visible(False)\n",
    "\n",
    "# set alpha for the rest of the bars\n",
    "for i, patch in enumerate(ax.patches):\n",
    "    patch.set_alpha(0.75)\n",
    "\n",
    "# Create a custom legend\n",
    "handles = [plt.Rectangle((0,0),1,1, color=row_colors[name]) for name in plot_res.columns]\n",
    "legend = ax.legend(handles, plot_res.columns, \n",
    "          title=\"Prompt strategy\", \n",
    "          bbox_to_anchor=(0.5, -0.12), ncol=2,\n",
    "          borderaxespad=1,\n",
    "          loc='upper center',\n",
    "          fontsize=9,\n",
    "          title_fontsize=9\n",
    "          )\n",
    "legend.get_frame().set_facecolor('white')\n",
    "\n",
    "# set background and grid color\n",
    "ax.set_facecolor('white')\n",
    "ax.grid(axis='x', linestyle='--', color='lightgray', linewidth=0.8)\n",
    "\n",
    "# save\n",
    "save = True\n",
    "if save == True:\n",
    "    plt.savefig('./figures/Figure2_accuracyPromptLLMbar.jpeg', dpi=500, bbox_inches='tight')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 2C-D. Distribution of the length of unstructured FDA-approval 'Indication and Usage' section and structured FDA-approval indications"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "# function to calculate IQR (interquartile range)\n",
    "def calc_iqr(chunk_size_list):\n",
    "    q1 = np.percentile(chunk_size_list, 25)\n",
    "    q3 = np.percentile(chunk_size_list, 75)\n",
    "    iqr = f'{q1}-{q3}'\n",
    "    return(iqr)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Unstructured dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "56"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# load unstructured context derived from FDA drug label indication and usage sections (deduplicated, full)\n",
    "with open(os.path.join(root_dir,\"data/unstructured_context_chunks.json\"), \"r\") as f:\n",
    "    unstructured_dataset = json.load(f)\n",
    "    \n",
    "len(unstructured_dataset)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "# chunks: 56\n",
      "Min: 241\n",
      "Max: 9883\n",
      "Mean: 1003.5\n",
      "Median: 734.5\n",
      "IQR: 552.0-976.75\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 400x300 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# get chunk size\n",
    "unstruc_chunk_size=[len(chunk) for chunk in unstructured_dataset]\n",
    "print(\"# chunks: \"+str(len(unstruc_chunk_size)))\n",
    "print(\"Min: \"+str(np.min(unstruc_chunk_size)))\n",
    "print(\"Max: \"+str(np.max(unstruc_chunk_size)))\n",
    "print(\"Mean: \"+str(np.mean(unstruc_chunk_size)))\n",
    "print(\"Median: \"+str(np.median(unstruc_chunk_size)))\n",
    "print(\"IQR: \"+str(calc_iqr(unstruc_chunk_size)))\n",
    "\n",
    "# set figure size and subplot\n",
    "plt.rcParams[\"figure.figsize\"] = [3.5, 3]\n",
    "fig, ax = plt.subplots(tight_layout=True, figsize=(4,3))\n",
    "\n",
    "# set color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# histogram with KDE\n",
    "n_bins=35\n",
    "sns.histplot(unstruc_chunk_size, bins=n_bins, kde=True, stat='count',\n",
    "             color='royalblue', alpha=0.5, edgecolor='white', ax=ax)\n",
    "\n",
    "# median line\n",
    "plt.axvline(np.median(unstruc_chunk_size), color='black', \n",
    "            linestyle='--', linewidth=1.5, label='Median', alpha=1)\n",
    "\n",
    "# x, y labels and ticks\n",
    "ax.set_xlabel('Length of unstructured indication section', fontsize=11)\n",
    "ax.set_ylabel('Frequency', fontsize=11) # raw counts\n",
    "\n",
    "# remove top and right border\n",
    "ax.spines['top'].set_visible(False)\n",
    "ax.spines['right'].set_visible(False)\n",
    "\n",
    "# add the legend\n",
    "# plt.legend()\n",
    "ax.legend(ncol=1, frameon=False)\n",
    "\n",
    "# save plot\n",
    "save = True\n",
    "if save == True:\n",
    "    plt.savefig('./figures/Figure2_unstructuredlength_dist.jpeg', dpi=500, bbox_inches='tight')\n",
    "\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Structured dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "234"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# load structured context derived from moalmanac data fields\n",
    "with open(os.path.join(root_dir,\"data/structured_context_chunks.json\"), \"r\") as f:\n",
    "    structured_dataset = json.load(f)\n",
    "\n",
    "len(structured_dataset)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "# chunks: 234\n",
      "Min: 489\n",
      "Max: 1178\n",
      "Mean: 761.8760683760684\n",
      "Median: 733.5\n",
      "IQR: 649.25-827.0\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 400x300 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# get chunk size\n",
    "struc_chunk_size=[len(chunk) for chunk in structured_dataset]\n",
    "print(\"# chunks: \"+str(len(struc_chunk_size)))\n",
    "print(\"Min: \"+str(np.min(struc_chunk_size)))\n",
    "print(\"Max: \"+str(np.max(struc_chunk_size)))\n",
    "print(\"Mean: \"+str(np.mean(struc_chunk_size)))\n",
    "print(\"Median: \"+str(np.median(struc_chunk_size)))\n",
    "print(\"IQR: \"+str(calc_iqr(struc_chunk_size)))\n",
    "\n",
    "# set figure size and subplot\n",
    "plt.rcParams[\"figure.figsize\"] = [3.5, 3]\n",
    "fig, ax = plt.subplots(tight_layout=True, figsize=(4,3))\n",
    "\n",
    "# set color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# histogram with KDE\n",
    "n_bins=35\n",
    "sns.histplot(struc_chunk_size, bins=n_bins, kde=True, stat='count',\n",
    "             color='royalblue', alpha=0.5, edgecolor='white', ax=ax)\n",
    "\n",
    "# median line\n",
    "plt.axvline(np.median(struc_chunk_size), color='black', \n",
    "            linestyle='--', linewidth=1.5, label='Median', alpha=1)\n",
    "\n",
    "# x, y labels and ticks\n",
    "ax.set_xlabel('Length of structured indication section', fontsize=11)\n",
    "ax.set_ylabel('Frequency', fontsize=11) # raw counts\n",
    "\n",
    "# remove top and right border\n",
    "ax.spines['top'].set_visible(False)\n",
    "ax.spines['right'].set_visible(False)\n",
    "\n",
    "# add legend\n",
    "ax.legend(ncol=1, frameon=False)\n",
    "\n",
    "# save plot\n",
    "save = True\n",
    "if save == True:\n",
    "    plt.savefig('./figures/Figure2_structuredlength_dist.jpeg', dpi=500, bbox_inches='tight')\n",
    "\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 3A. Impact of RAG integration on LLM performance with unstructured and structured database"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Unstructured: 0.7307692307692307, 0.8504273504273504\n",
      "Structured: 0.905982905982906, 0.9871794871794872\n",
      "LLM-only: 0.5384615384615384, 0.6923076923076923\n"
     ]
    }
   ],
   "source": [
    "# Load RAG-LLM results\n",
    "rag_struc_res_dict_0 = load_object(filename=os.path.join(root_dir, 'output/RAG_res_mistnemo/structured/RAGstra0n5temp0.0_res_dict.pkl'))\n",
    "rag_unstruc_res_dict_0 = load_object(filename=os.path.join(root_dir, 'output/RAG_res_mistnemo/unstructured/RAGstra0n5temp0.0_res_dict.pkl'))\n",
    "\n",
    "# Calculate evaluation metrics for the RAG-LLM output from the first iteration\n",
    "unstruc_results = calc_eval_metrics(rag_unstruc_res_dict_0['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "struc_results = calc_eval_metrics(rag_struc_res_dict_0['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "llm_results = llm_eval_res['llm_mistnemo_eval_res_0']\n",
    "\n",
    "print(f\"Unstructured: {unstruc_results['avg_exact_match_acc']}, {unstruc_results['avg_partial_match_acc']}\")\n",
    "print(f\"Structured: {struc_results['avg_exact_match_acc']}, {struc_results['avg_partial_match_acc']}\")\n",
    "print(f\"LLM-only: {llm_results['avg_exact_match_acc']}, {llm_results['avg_partial_match_acc']}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Run McNemar's test for statistical significance"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "LLM-only vs. RAG-LLM unstructured"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Exact match test Statistic: 23.901234567901234\n",
      "Exact match p-value: 1.0140670844453472e-06\n",
      "Partial match test Statistic: 18.253521126760564\n",
      "Partial match p-value: 1.9336816600800142e-05\n",
      "Significant difference in exact match acc: True\n",
      "Significant difference in partial match acc: True\n"
     ]
    }
   ],
   "source": [
    "# Create contingency table\n",
    "exact_table=create_mcnemar_table(llm_results['exact_match_acc'], unstruc_results['exact_match_acc'])\n",
    "partial_table=create_mcnemar_table(llm_results['partial_match_acc'], unstruc_results['partial_match_acc'])\n",
    "\n",
    "# Perform McNemar's test (exact=True if b+c < 25)\n",
    "exact_result = conduct_mcnemar_test(exact_table) \n",
    "partial_result = conduct_mcnemar_test(partial_table) \n",
    "\n",
    "# Print results\n",
    "print(f\"Exact match test Statistic: {exact_result.statistic}\")\n",
    "print(f\"Exact match p-value: {exact_result.pvalue}\")\n",
    "print(f\"Partial match test Statistic: {partial_result.statistic}\")\n",
    "print(f\"Partial match p-value: {partial_result.pvalue}\")\n",
    "\n",
    "# Print interpretations\n",
    "alpha = 0.05\n",
    "print(f\"Significant difference in exact match acc: {exact_result.pvalue < alpha}\")\n",
    "print(f\"Significant difference in partial match acc: {partial_result.pvalue < alpha}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "RAG-LLM unstructured vs. RAG-LLM structured"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Exact match test Statistic: 25.396825396825395\n",
      "Exact match p-value: 4.6668548096211404e-07\n",
      "Partial match test Statistic: 28.264705882352942\n",
      "Partial match p-value: 1.0580771204088795e-07\n",
      "Significant difference in exact match acc: True\n",
      "Significant difference in partial match acc: True\n"
     ]
    }
   ],
   "source": [
    "# Create contingency table\n",
    "exact_table=create_mcnemar_table(unstruc_results['exact_match_acc'], struc_results['exact_match_acc'])\n",
    "partial_table=create_mcnemar_table(unstruc_results['partial_match_acc'], struc_results['partial_match_acc'])\n",
    "\n",
    "# Perform McNemar's test\n",
    "exact_result = conduct_mcnemar_test(exact_table) \n",
    "partial_result = conduct_mcnemar_test(partial_table) \n",
    "\n",
    "# Print results\n",
    "print(f\"Exact match test Statistic: {exact_result.statistic}\")\n",
    "print(f\"Exact match p-value: {exact_result.pvalue}\")\n",
    "print(f\"Partial match test Statistic: {partial_result.statistic}\")\n",
    "print(f\"Partial match p-value: {partial_result.pvalue}\")\n",
    "\n",
    "# Print interpretations\n",
    "alpha = 0.05\n",
    "print(f\"Significant difference in exact match acc: {exact_result.pvalue < alpha}\")\n",
    "print(f\"Significant difference in partial match acc: {partial_result.pvalue < alpha}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Plot bar graph"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "plot_res=pd.DataFrame({\n",
    "    'Unstructured RAG-LLM': [unstruc_results['avg_partial_match_acc'], unstruc_results['avg_exact_match_acc']],\n",
    "    'Structured RAG-LLM': [struc_results['avg_partial_match_acc'], struc_results['avg_exact_match_acc']],\n",
    "}, index=['Partial match accuracy','Exact match accuracy'])\n",
    "plot_res=plot_res*100"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 450x370 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# set figure size\n",
    "plt.rcParams[\"figure.figsize\"] = [4.5, 3.7]\n",
    "\n",
    "# set color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# create a mapping of rownames to colors\n",
    "row_colors = dict(zip(plot_res.columns, [cols[23],cols[6]]))\n",
    "\n",
    "# create bar plot\n",
    "ax=plot_res.plot(kind='bar', color=[row_colors[name] for name in plot_res.columns], width=0.6, legend=False)\n",
    "\n",
    "# add text\n",
    "for bar in ax.patches:\n",
    "    x = bar.get_x() + bar.get_width() / 2\n",
    "    y = bar.get_height()\n",
    "    ax.text(x, y+0.02, f'{y:.2f}', ha='center', va='bottom', fontsize=9)\n",
    "    \n",
    "# x, y labels, ticks, grid\n",
    "ax.set_xlabel('')\n",
    "ax.set_ylabel('Accuracy (%)', fontsize=12)\n",
    "ax.tick_params(axis='x', labelsize=9, rotation=0)\n",
    "ax.tick_params(axis='y', labelsize=10)\n",
    "ax.set_facecolor(color='white')\n",
    "\n",
    "# add LLM accuracy horizontal line and text\n",
    "ax.axhline(y=llm_results['avg_exact_match_acc']*100, color='black', linestyle='--', linewidth=0.8, alpha=0.8)\n",
    "ax.axhline(y=llm_results['avg_partial_match_acc']*100, color='black', linestyle='--', linewidth=0.8, alpha=0.8)\n",
    "ax.text(\n",
    "    x=len(plot_res.columns) - 0.6,  \n",
    "    y=llm_results['avg_exact_match_acc']*100 + 1,  \n",
    "    s=f\"LLM exact: {llm_results['avg_exact_match_acc']*100:.2f}%\",\n",
    "    color='black', fontsize=9\n",
    "    )    \n",
    "ax.text(\n",
    "    x=len(plot_res.columns) - 0.6,  \n",
    "    y=llm_results['avg_partial_match_acc']*100 + 1,  \n",
    "    s=f\"LLM partial: {llm_results['avg_partial_match_acc']*100:.2f}%\",\n",
    "    color='black', fontsize=9\n",
    "    )    \n",
    "\n",
    "# remove border\n",
    "for spine in ax.spines.values():\n",
    "    spine.set_visible(False)\n",
    "    \n",
    "# set alpha for the rest of the bars\n",
    "for i, patch in enumerate(ax.patches):\n",
    "    patch.set_alpha(0.75)\n",
    "\n",
    "# create a custom legend\n",
    "handles = [plt.Rectangle((0,0),1,1, color=row_colors[name]) for name in plot_res.columns]\n",
    "legend = ax.legend(handles, plot_res.columns, \n",
    "          title=False, \n",
    "          bbox_to_anchor=(0.5, -0.12), ncol=2,\n",
    "          frameon=False,\n",
    "          borderaxespad=1,\n",
    "          loc='upper center',\n",
    "          fontsize=9,\n",
    "          title_fontsize=9\n",
    "          ) \n",
    "legend.get_frame().set_facecolor('white')\n",
    "\n",
    "# save\n",
    "save = True\n",
    "if save == True:\n",
    "    plt.savefig('./figures/Figure3_accuracyRAGLLMbar.jpeg', dpi=500, bbox_inches='tight')\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 3B. Impact on other evaluation metrics: precision, recall, f1, specificity"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 500x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from math import pi\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# Color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# Metrics\n",
    "metrics = ['Exact accuracy', 'Partial accuracy', 'Precision', 'Recall', 'F1 Score', 'Specificity']\n",
    "\n",
    "# Values for unstructured model\n",
    "values_unstruc = [\n",
    "    unstruc_results['avg_exact_match_acc'],\n",
    "    unstruc_results['avg_partial_match_acc'],\n",
    "    unstruc_results['avg_precision'], \n",
    "    unstruc_results['avg_recall'],\n",
    "    unstruc_results['avg_f1'],\n",
    "    unstruc_results['avg_specificity']\n",
    "    ]\n",
    "values_unstruc += values_unstruc[:1] # close the loop\n",
    "\n",
    "# Values for structured model\n",
    "values_struc = [\n",
    "    struc_results['avg_exact_match_acc'],\n",
    "    struc_results['avg_partial_match_acc'],\n",
    "    struc_results['avg_precision'], \n",
    "    struc_results['avg_recall'],\n",
    "    struc_results['avg_f1'],\n",
    "    struc_results['avg_specificity']\n",
    "    ]\n",
    "values_struc += values_struc[:1]\n",
    "\n",
    "# Radar chart setup\n",
    "angles = [n / float(len(metrics)) * 2 * pi for n in range(len(metrics))]\n",
    "angles += angles[:1]\n",
    "\n",
    "# Set up the plot\n",
    "plt.figure(figsize=(5, 5))\n",
    "ax = plt.subplot(111, polar=True)\n",
    "\n",
    "# Plot the models\n",
    "ax.plot(angles, values_unstruc, color=cols[23], linewidth=2, linestyle='solid',\n",
    "        label='RAG with unstructured database')\n",
    "ax.plot(angles, values_struc, color=cols[6], linewidth=2, linestyle='solid', \n",
    "        label='RAG with structured database')\n",
    "\n",
    "# Annotate each metric value\n",
    "for i in range(len(metrics)):\n",
    "    ax.text(angles[i], values_unstruc[i] - 0.08, \n",
    "            f\"{values_unstruc[i]:.2f}\",\n",
    "            color='black', fontsize=11, ha='center', va='center')\n",
    "    ax.text(angles[i] - 0.08, values_struc[i] + 0.08, \n",
    "            f\"{values_struc[i]:.2f}\",\n",
    "            color='black', fontsize=11, ha='center', va='center')\n",
    "\n",
    "# Labels and ticks\n",
    "ax.set_ylim(0, 1.0)\n",
    "ax.tick_params(axis='y', labelsize=10)\n",
    "ax.set_xticks([])\n",
    "for i, metric in enumerate(metrics): # Manually set the position of the labels outside the chart\n",
    "    angle = angles[i]  \n",
    "    if angle == 0:  \n",
    "        ax.text(angle, 1.6, metric, horizontalalignment='center', verticalalignment='center', fontsize=17)       \n",
    "    else:\n",
    "        ax.text(angle, 1.3, metric, horizontalalignment='center', verticalalignment='center', fontsize=17)       \n",
    "\n",
    "# Save plot\n",
    "save = True\n",
    "if save == True:\n",
    "    plt.savefig('./figures/Figure3_ragllmPerformance_radar.jpeg', dpi=600, bbox_inches='tight')\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'exact_match_acc': 23.97660818713451, 'partial_match_acc': 16.08040201005026, 'avg_precision': 63.10070666928588, 'avg_recall': 19.820627802690677, 'avg_f1': 51.658880652544056, 'avg_specificity': 1.8842620713047666}\n",
      "Precision: 49.0 to 79.9\n",
      "F1-score: 55.7 to 84.4\n"
     ]
    }
   ],
   "source": [
    "# Calculate percent increase of evaluation metrics\n",
    "def perc_increase(old, new):\n",
    "    if old == 0:\n",
    "        if new == 0:\n",
    "            return 0  \n",
    "        return None  \n",
    "    return ((new - old) / old) * 100\n",
    "\n",
    "perc_increase_ls=[]\n",
    "for i in range(len(values_unstruc)):\n",
    "    perc_increase_ls.append(perc_increase(new=values_struc[i], old=values_unstruc[i]))\n",
    "\n",
    "print(dict(zip(['exact_match_acc', 'partial_match_acc','avg_precision','avg_recall','avg_f1','avg_specificity'],perc_increase_ls)))\n",
    "print(f'Precision: {values_unstruc[2]*100:.1f} to {values_struc[2]*100:.1f}')\n",
    "print(f'F1-score: {values_unstruc[4]*100:.1f} to {values_struc[4]*100:.1f}')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 3C. Accuracy of RAG-LLM across therapies, diseases and genomic alterations"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create df for plotting\n",
    "plot_df = moalmanac_data\n",
    "plot_df['RAGLLM_struc_res'] = struc_results['exact_match_acc']\n",
    "plot_df['RAGLLM_unstruc_res'] = unstruc_results['exact_match_acc']\n",
    "plot_df['oncotree_code'] = plot_df['oncotree_code'].fillna('Any solid tumor')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Accuracy across cancer types"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x500 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# set figure subplots\n",
    "fig, axes = plt.subplots(nrows=2, ncols=1, figsize=(8,5), gridspec_kw=dict(height_ratios=[1, 1]))\n",
    "\n",
    "# set color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# create accuracy dataframe \n",
    "df_all = pd.DataFrame()\n",
    "for col in ['RAGLLM_unstruc_res', 'RAGLLM_struc_res']:\n",
    "    df = pd.crosstab(plot_df['oncotree_code'], plot_df[col])\n",
    "    df['accuracy'] = df[True] / (df[True] + df[False])\n",
    "    df_all = pd.concat([df_all, df.rename(columns = {'accuracy':col})[col]], axis = 1)\n",
    "\n",
    "# add counts (number of relationships)\n",
    "group_cnt_df = pd.DataFrame.from_dict(Counter(plot_df['oncotree_code']), orient=\"index\", columns=[\"Number of relationships\"])\n",
    "df_all=df_all.merge(group_cnt_df, left_index=True, right_index=True)\n",
    "\n",
    "# sort by number of relationships (descending) \n",
    "df_all = df_all.sort_values(by=\"Number of relationships\", ascending=False)\n",
    "\n",
    "# create a mapping of names to colors\n",
    "struc_unstruc_colors = dict(zip(df_all.columns[0:2], [cols[23],cols[6]]))\n",
    "num_rel_color = cols[7]\n",
    "\n",
    "# create bar plot\n",
    "df_all[['RAGLLM_unstruc_res', 'RAGLLM_struc_res']].plot(kind='bar', color=struc_unstruc_colors, \n",
    "                                                        width=0.6, legend=False, ax=axes[1])\n",
    "df_all['Number of relationships'].plot(kind='bar', color=num_rel_color, width=0.6, legend=False, ax=axes[0])\n",
    "    \n",
    "# x, y label and ticks\n",
    "axes[0].set_ylabel('Number of entities', fontsize=12)\n",
    "axes[0].set_xticks([])\n",
    "axes[1].set_ylabel('Accuracy', fontsize=12)\n",
    "axes[1].set_xlabel('Cancer type', fontsize=12)\n",
    "axes[1].tick_params(axis='x', labelrotation=45, size=5)\n",
    "for label in axes[1].get_xticklabels():\n",
    "    label.set_ha('right') \n",
    "    label.set_rotation_mode('anchor')\n",
    "\n",
    "# set alpha for the rest of the bars\n",
    "for i, patch in enumerate(axes[0].patches):\n",
    "    patch.set_alpha(0.75)\n",
    "\n",
    "for i, patch in enumerate(axes[1].patches):\n",
    "    patch.set_alpha(0.75)\n",
    "\n",
    "# change background and grid color\n",
    "for ax in axes:\n",
    "    # change background color\n",
    "    ax.set_facecolor('white')\n",
    "    # change grid color\n",
    "    ax.grid(visible=True, axis='y', color='lightgray', linestyle='dotted')  \n",
    "\n",
    "# Save plot\n",
    "save = True\n",
    "if save == True:\n",
    "    plt.savefig('./figures/Figure3_cancerAcc_heatmap.jpeg', dpi=600, bbox_inches='tight')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "RAGLLM_unstruc_res",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "RAGLLM_struc_res",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "Number of relationships",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "perc_increase",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "oncotree_term",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "oncotree_code",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "13a56136-55b7-4b08-a66f-76b5dd023242",
       "rows": [
        [
         "30",
         "0.1",
         "1.0",
         "10",
         "900.0",
         "Melanoma",
         "MEL"
        ],
        [
         "0",
         "0.5",
         "1.0",
         "6",
         "100.0",
         "Chronic Myelogenous Leukemia",
         "CML"
        ],
        [
         "44",
         "0.6923076923076923",
         "1.0",
         "13",
         "44.44444444444445",
         "Peritoneal Serous Carcinoma",
         "PSEC"
        ],
        [
         "6",
         "0.6666666666666666",
         "0.9",
         "30",
         "35.00000000000001",
         "Non-Small Cell Lung Cancer",
         "NSCLC"
        ]
       ],
       "shape": {
        "columns": 6,
        "rows": 4
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>RAGLLM_unstruc_res</th>\n",
       "      <th>RAGLLM_struc_res</th>\n",
       "      <th>Number of relationships</th>\n",
       "      <th>perc_increase</th>\n",
       "      <th>oncotree_term</th>\n",
       "      <th>oncotree_code</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>0.100000</td>\n",
       "      <td>1.0</td>\n",
       "      <td>10</td>\n",
       "      <td>900.000000</td>\n",
       "      <td>Melanoma</td>\n",
       "      <td>MEL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0.500000</td>\n",
       "      <td>1.0</td>\n",
       "      <td>6</td>\n",
       "      <td>100.000000</td>\n",
       "      <td>Chronic Myelogenous Leukemia</td>\n",
       "      <td>CML</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>0.692308</td>\n",
       "      <td>1.0</td>\n",
       "      <td>13</td>\n",
       "      <td>44.444444</td>\n",
       "      <td>Peritoneal Serous Carcinoma</td>\n",
       "      <td>PSEC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>0.666667</td>\n",
       "      <td>0.9</td>\n",
       "      <td>30</td>\n",
       "      <td>35.000000</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>NSCLC</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    RAGLLM_unstruc_res  RAGLLM_struc_res  Number of relationships  \\\n",
       "30            0.100000               1.0                       10   \n",
       "0             0.500000               1.0                        6   \n",
       "44            0.692308               1.0                       13   \n",
       "6             0.666667               0.9                       30   \n",
       "\n",
       "    perc_increase                 oncotree_term oncotree_code  \n",
       "30     900.000000                      Melanoma           MEL  \n",
       "0      100.000000  Chronic Myelogenous Leukemia           CML  \n",
       "44      44.444444   Peritoneal Serous Carcinoma          PSEC  \n",
       "6       35.000000    Non-Small Cell Lung Cancer         NSCLC  "
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# calculate percentage increase\n",
    "df_all['perc_increase'] = df_all.apply(lambda row: perc_increase(old=row['RAGLLM_unstruc_res'], \n",
    "                                                                 new=row['RAGLLM_struc_res']), \n",
    "                                       axis=1)\n",
    "\n",
    "df_all_perc=df_all.sort_values(by=\"perc_increase\", ascending=False)\n",
    "\n",
    "# top cancer types with percentage increase >= 30 and number of relationships >= 5\n",
    "df_all_perc.loc[(df_all_perc['perc_increase'] >= 30) & (df_all_perc['Number of relationships'] >= 5), :]\\\n",
    "    .merge(plot_df[['oncotree_term','oncotree_code']], \n",
    "           left_index=True, right_on='oncotree_code', how='inner')\\\n",
    "               .drop_duplicates()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Accuracy across therapy types"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [],
   "source": [
    "# clean therapy strategy names\n",
    "plot_df['therapy_strategy_2']=plot_df['therapy_strategy'].replace(r'inhibition|targets|signaling','', regex=True).str.replace(r'\\s+', ' ', regex=True).replace(r'chemotherapy|Chemotherapy','chemo', regex=True).str.strip()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x500 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# set figure subplots\n",
    "fig, axes = plt.subplots(nrows=2, ncols=1, figsize=(8,5), gridspec_kw=dict(height_ratios=[1, 1]))\n",
    "\n",
    "# set color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# create accuracy dataframe \n",
    "df_all = pd.DataFrame()\n",
    "for col in ['RAGLLM_unstruc_res', 'RAGLLM_struc_res']:\n",
    "    df = pd.crosstab(plot_df['therapy_strategy_2'], plot_df[col])\n",
    "    df['accuracy'] = df[True] / (df[True] + df[False])\n",
    "    df_all = pd.concat([df_all, df.rename(columns = {'accuracy':col})[col]], axis = 1)\n",
    "\n",
    "# add counts (number of relationships)\n",
    "group_cnt_df = pd.DataFrame.from_dict(Counter(plot_df['therapy_strategy_2']), orient=\"index\", columns=[\"Number of relationships\"])\n",
    "df_all = df_all.merge(group_cnt_df, left_index=True, right_index=True)\n",
    "\n",
    "# sort by number of relationships (descending) \n",
    "df_all = df_all.sort_values(by=\"Number of relationships\", ascending=False)\n",
    "\n",
    "# create a mapping of names to colors\n",
    "struc_unstruc_colors = dict(zip(df_all.columns[0:2], [cols[23],cols[6]]))\n",
    "num_rel_color = cols[7]\n",
    "\n",
    "# create bar plot\n",
    "df_all[['RAGLLM_unstruc_res', 'RAGLLM_struc_res']].plot(kind='bar', color=struc_unstruc_colors, width=0.6, legend=False, ax=axes[1])\n",
    "df_all['Number of relationships'].plot(kind='bar', color=num_rel_color, width=0.6, legend=False, ax=axes[0])\n",
    "    \n",
    "# x, y label and ticks\n",
    "axes[0].set_ylabel('Number of entities', fontsize=12)\n",
    "axes[0].set_xticks([])\n",
    "axes[1].set_ylabel('Accuracy', fontsize=12)\n",
    "axes[1].set_xlabel('Therapy strategy', fontsize=12)\n",
    "axes[1].tick_params(axis='x', labelrotation=45, size=5)\n",
    "for label in axes[1].get_xticklabels():\n",
    "    label.set_ha('right') \n",
    "    label.set_rotation_mode('anchor') \n",
    "\n",
    "# set alpha for the rest of the bars\n",
    "for i, patch in enumerate(axes[0].patches):\n",
    "    patch.set_alpha(0.75)\n",
    "\n",
    "for i, patch in enumerate(axes[1].patches):\n",
    "    patch.set_alpha(0.75)\n",
    "\n",
    "# change background and grid color\n",
    "for ax in axes:\n",
    "    # change background color\n",
    "    ax.set_facecolor('white')\n",
    "    # change grid color\n",
    "    ax.grid(visible=True, axis='y', color='lightgray', linestyle='dotted')\n",
    "\n",
    "# save plot\n",
    "save = True\n",
    "if save == True:\n",
    "    plt.savefig('./figures/Figure3_therapyAcc_heatmap.jpeg', dpi=600, bbox_inches='tight')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_unstruc_res",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "RAGLLM_struc_res",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "Number of relationships",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "perc_increase",
         "rawType": "float64",
         "type": "float"
        }
       ],
       "ref": "d8cf1bf0-819b-46f6-83fc-b7a052e50aee",
       "rows": [
        [
         "B-RAF",
         "0.3333333333333333",
         "1.0",
         "6",
         "200.00000000000006"
        ],
        [
         "Antiandrogen + PARP",
         "0.1875",
         "0.5",
         "16",
         "166.66666666666669"
        ],
        [
         "B-RAF + MEK",
         "0.42857142857142855",
         "1.0",
         "7",
         "133.33333333333331"
        ],
        [
         "RET",
         "0.6666666666666666",
         "1.0",
         "6",
         "50.000000000000014"
        ],
        [
         "BCR-ABL",
         "0.7272727272727273",
         "1.0",
         "11",
         "37.49999999999999"
        ],
        [
         "MET",
         "0.75",
         "1.0",
         "8",
         "33.33333333333333"
        ]
       ],
       "shape": {
        "columns": 4,
        "rows": 6
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>RAGLLM_unstruc_res</th>\n",
       "      <th>RAGLLM_struc_res</th>\n",
       "      <th>Number of relationships</th>\n",
       "      <th>perc_increase</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>B-RAF</th>\n",
       "      <td>0.333333</td>\n",
       "      <td>1.0</td>\n",
       "      <td>6</td>\n",
       "      <td>200.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Antiandrogen + PARP</th>\n",
       "      <td>0.187500</td>\n",
       "      <td>0.5</td>\n",
       "      <td>16</td>\n",
       "      <td>166.666667</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>B-RAF + MEK</th>\n",
       "      <td>0.428571</td>\n",
       "      <td>1.0</td>\n",
       "      <td>7</td>\n",
       "      <td>133.333333</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>RET</th>\n",
       "      <td>0.666667</td>\n",
       "      <td>1.0</td>\n",
       "      <td>6</td>\n",
       "      <td>50.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>BCR-ABL</th>\n",
       "      <td>0.727273</td>\n",
       "      <td>1.0</td>\n",
       "      <td>11</td>\n",
       "      <td>37.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>MET</th>\n",
       "      <td>0.750000</td>\n",
       "      <td>1.0</td>\n",
       "      <td>8</td>\n",
       "      <td>33.333333</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                     RAGLLM_unstruc_res  RAGLLM_struc_res  \\\n",
       "B-RAF                          0.333333               1.0   \n",
       "Antiandrogen + PARP            0.187500               0.5   \n",
       "B-RAF + MEK                    0.428571               1.0   \n",
       "RET                            0.666667               1.0   \n",
       "BCR-ABL                        0.727273               1.0   \n",
       "MET                            0.750000               1.0   \n",
       "\n",
       "                     Number of relationships  perc_increase  \n",
       "B-RAF                                      6     200.000000  \n",
       "Antiandrogen + PARP                       16     166.666667  \n",
       "B-RAF + MEK                                7     133.333333  \n",
       "RET                                        6      50.000000  \n",
       "BCR-ABL                                   11      37.500000  \n",
       "MET                                        8      33.333333  "
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# calculate percentage increase dataframe\n",
    "df_all['perc_increase'] = df_all.apply(lambda row: perc_increase(old=row['RAGLLM_unstruc_res'], \n",
    "                                                                 new=row['RAGLLM_struc_res']), \n",
    "                                       axis=1)\n",
    "\n",
    "df_all_perc=df_all.sort_values(by=\"perc_increase\", ascending=False)\n",
    "\n",
    "# top cancer types with percentage increase >= 30 and number of relationships >= 5\n",
    "df_all_perc.loc[(df_all_perc['perc_increase'] >= 30) & (df_all_perc['Number of relationships'] >= 5), :]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 4A-B. RAG-LLM performance on real-world questions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Question_index",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "prompt",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Asking_therapy",
         "rawType": "bool",
         "type": "boolean"
        },
        {
         "name": "Given_biomarker",
         "rawType": "bool",
         "type": "boolean"
        },
        {
         "name": "Question_category",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Is_there_an_approval",
         "rawType": "bool",
         "type": "boolean"
        },
        {
         "name": "Groundtruth_answers",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Groundtruth_therapies",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "7ff8966d-183d-4caa-b73d-544572f81b16",
       "rows": [
        [
         "0",
         "q0",
         "What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? ",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "erdafitinib",
         "[{'erdafitinib'}]"
        ],
        [
         "1",
         "q1",
         "Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "PARP inhibitors are not yet approved for the treatment of patients with leimyosarcoma with mutations in DNA repair pathway genes.",
         "[]"
        ],
        [
         "2",
         "q2",
         "Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "No, no ALK inhibitors are currently approved for use for the treatment of patients with rhabdomyosarcoma, nevermind TFCP2 fusion positive rhabdomyosarcoma.",
         "[]"
        ],
        [
         "3",
         "q3",
         "For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "The following therapy and combination therapies are approved by the US FDA for use for the treatment of patients with BRCA2 mutated metastatic castration resistant prostate cancer: olaparib; abiraterone, olaparib, and prednisone; enzalutamide and talazoparib; abiraterone acetate and niraparib; and rucaparib.",
         "[{'olaparib'}, {'prednisone', 'olaparib', 'abiraterone'}, {'talazoparib', 'enzalutamide'}, {'abiraterone acetate', 'niraparib'}, {'rucaparib'}]"
        ],
        [
         "4",
         "q4",
         "For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?",
         "True",
         "True",
         "given disease and biomarker, return drugs; HER2-related",
         "True",
         "TDM-1 (ado-trastuzumab emtansine (Kadcyla))",
         "[{'ado-trastuzumab emtansine'}]"
        ],
        [
         "5",
         "q5",
         "For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "Yes, the TRK inhibitors Entrectinib and Larotrectinib are approved for use for the treatment of patients with any solid tumor harboring an NTRK1/2/3 fusion. Repotrectinib was also approved after the release of the version of MOAlamanc used in the study.",
         "[{'entrectinib'}, {'larotrectinib'}]"
        ],
        [
         "6",
         "q6",
         "For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "Yes, Keytruda (pembrolizumab) is approved by the FDA for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>=10 mutations/megabase (mut/Mb)] solid tumors.",
         "[{'pembrolizumab'}]"
        ],
        [
         "7",
         "q7",
         "What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "While no drugs are approved for use by the US FDA specifically for the treatment of patients with NTRK fusion positive pancreatic adenocarcinoma, a few therapies have received approval for use in any solid tumor that harbors an NTRK fusion. These include: Entrectinib, Larotrectinib. Repotrectinib was also approved after the release of the version of MOAlamanc used in the study.",
         "[{'entrectinib'}, {'larotrectinib'}]"
        ],
        [
         "8",
         "q8",
         "What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "There are not currently approved therapies for use from the US FDA for the treatment of patients with FGFR2 mutated bladder cancer.",
         "[]"
        ],
        [
         "9",
         "q9",
         "A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any treatments for use for the treatment of patients with localized or relapsed Ewing sarcoma with STAG2 mutations.",
         "[]"
        ],
        [
         "10",
         "q10",
         "A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma",
         "[]"
        ],
        [
         "11",
         "q11",
         "I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma",
         "[]"
        ],
        [
         "12",
         "q12",
         "My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma",
         "[]"
        ],
        [
         "13",
         "q13",
         "For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with osteosarcoma",
         "[]"
        ],
        [
         "14",
         "q14",
         "Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?",
         "True",
         "True",
         "given disease and biomarker, return drugs; not included in the version of MOAlamanc used in the study",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with KMT2A translocation positive AML. However, Revumenib was approved on November, 2024, which is not included in the version of MOAlamanc used in the study.",
         "[]"
        ],
        [
         "15",
         "q15",
         "For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with medulloblastoma, does not have access to clinical trial information.",
         "[]"
        ],
        [
         "16",
         "q16",
         "For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with hepatoblastoma. However, there is clinical evidence that CTNNB1 is associated with favorable prognosis in patients with medulloblastoma.",
         "[]"
        ],
        [
         "17",
         "q17",
         "I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?",
         "True",
         "True",
         "given disease and biomarker, return drugs; HER2-related",
         "True",
         "Two therapeutic hypotheses to consider for this patient are either PARP or PI3K/Akt/mTOR inhibition, though all treatment options are indicated for patients that have HER2-negative breast cancer. For first line treatment, talazoparib is approved for use and indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. For second line treatments, options will vary depending on the type of first line treatment. Capivasertib in combination with fulvestrant is approved for use for the treatment of adult patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. Olaparib is also approved for use for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative (i) metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting; and (ii) high risk early breast cancer who have been treated with chemotherapy in the neoadjuvant or adjuvant setting.",
         "[{'talazoparib'}, {'capivasertib', 'fulvestrant'}, {'olaparib'}]"
        ],
        [
         "18",
         "q18",
         "I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?",
         "True",
         "True",
         "given disease and biomarker, return drugs; HER2-related",
         "True",
         "While this version of MOAlmanac does not directly curate HER2+ status as a biomarker, a number of FDA approvals and companion diagnostics include ERBB2 amplifications for approvals based on HER2+. For FDA approvals for patients with breast cancer: Ado-Trastuzumab Emtansine; Capecitabine + Trastuzumab + Tucatinib; Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab; Lapatinib; Margetuximab-cmkb + Chemotherapy; Neratinib; Neratinib + Capecitabine; Pertuzumab + Trastuzumab; Trastuzumab; Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab",
         "[{'ado-trastuzumab emtansine'}, {'trastuzumab', 'tucatinib', 'capecitabine'}, {'trastuzumab', 'hyaluronidase-zzxf', 'pertuzumab', 'chemotherapy'}, {'lapatinib'}, {'chemotherapy', 'margetuximab-cmkb'}, {'neratinib'}, {'capecitabine', 'neratinib'}, {'trastuzumab', 'pertuzumab'}, {'trastuzumab'}, {'trastuzumab', 'pertuzumab', 'hyaluronidase-zzxf', 'docetaxel'}, {'trastuzumab', 'pertuzumab', 'docetaxel'}]"
        ],
        [
         "19",
         "q19",
         "I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?",
         "True",
         "True",
         "given disease and biomarker, return drugs; not included in the version of MOAlamanc used in the study",
         "True",
         "Either T-DXd or SG could be used; we generally use SG at this point given a large phase III trial (ASCENT) with PFS and OS benefit. Destiny-BREAST04 had a smaller cohort of TNBC. Both T-DXd and SG are FDA approved for MBC after 1+ prior lines of chemotherapy; SG is approved for HER2 null, while T-DXd is approved for HER2-low or -ultralow. T-DXd is associated with higher rates of interstitial lung disease, and cardiac function must be monitored given anti-HER2 activity. SG has more dense alopecia and higher rates of neutropenia.",
         "[{'sacituzumab govitecan'}, {'trastuzumab deruxtecan'}]"
        ],
        [
         "20",
         "q20",
         "If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "The US FDA has approved Erdafitnib for use for the treatment of patients with locally advanced or metastatic  urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy.",
         "[{'erdafitinib'}]"
        ]
       ],
       "shape": {
        "columns": 8,
        "rows": 21
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question_index</th>\n",
       "      <th>prompt</th>\n",
       "      <th>Asking_therapy</th>\n",
       "      <th>Given_biomarker</th>\n",
       "      <th>Question_category</th>\n",
       "      <th>Is_there_an_approval</th>\n",
       "      <th>Groundtruth_answers</th>\n",
       "      <th>Groundtruth_therapies</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>q0</td>\n",
       "      <td>What is the first-line treatment of metastatic...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>erdafitinib</td>\n",
       "      <td>[{'erdafitinib'}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>q1</td>\n",
       "      <td>Are PARP inhibitors used for patients with lei...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>PARP inhibitors are not yet approved for the t...</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>q2</td>\n",
       "      <td>Are ALK inhibitors approved for use in TFCP2 f...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>No, no ALK inhibitors are currently approved f...</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>q3</td>\n",
       "      <td>For a patient with cancer metastatic prostate ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>The following therapy and combination therapie...</td>\n",
       "      <td>[{'olaparib'}, {'prednisone', 'olaparib', 'abi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>q4</td>\n",
       "      <td>For a patient with HER2+ breast cancer after n...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; HER...</td>\n",
       "      <td>True</td>\n",
       "      <td>TDM-1 (ado-trastuzumab emtansine (Kadcyla))</td>\n",
       "      <td>[{'ado-trastuzumab emtansine'}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>q5</td>\n",
       "      <td>For patients with advanced cancer and with NTR...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes, the TRK inhibitors Entrectinib and Larotr...</td>\n",
       "      <td>[{'entrectinib'}, {'larotrectinib'}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>q6</td>\n",
       "      <td>For patients with advanced cancer and with hig...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes, Keytruda (pembrolizumab) is approved by t...</td>\n",
       "      <td>[{'pembrolizumab'}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>q7</td>\n",
       "      <td>What FDA-approved therapies exist for a Stage ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>While no drugs are approved for use by the US ...</td>\n",
       "      <td>[{'entrectinib'}, {'larotrectinib'}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>q8</td>\n",
       "      <td>What are available FDA-approved targeted thera...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>There are not currently approved therapies for...</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>q9</td>\n",
       "      <td>A patient with localized Ewing sarcoma has a S...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any treatments...</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>q10</td>\n",
       "      <td>A patient with relapsed high-risk neuroblastom...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>q11</td>\n",
       "      <td>I have a 3 year old patient with Neuroblastoma...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>q12</td>\n",
       "      <td>My 20 year old patient with ALK mutated Neurob...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>q13</td>\n",
       "      <td>For a 17-year-old osteosarcoma patient with 50...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>q14</td>\n",
       "      <td>Is there an optimal drug combination to minimi...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; not...</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>q15</td>\n",
       "      <td>For a 4 year old patient with medulloblastoma,...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>q16</td>\n",
       "      <td>For toddler with unresectable hepatoblastoma a...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>q17</td>\n",
       "      <td>I have a patient with de novo metastatic HR+ b...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; HER...</td>\n",
       "      <td>True</td>\n",
       "      <td>Two therapeutic hypotheses to consider for thi...</td>\n",
       "      <td>[{'talazoparib'}, {'capivasertib', 'fulvestran...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>q18</td>\n",
       "      <td>I have a patient with an initial diagnosis of ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; HER...</td>\n",
       "      <td>True</td>\n",
       "      <td>While this version of MOAlmanac does not direc...</td>\n",
       "      <td>[{'ado-trastuzumab emtansine'}, {'trastuzumab'...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>q19</td>\n",
       "      <td>I have a patient with metastatic HR-negative, ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; not...</td>\n",
       "      <td>True</td>\n",
       "      <td>Either T-DXd or SG could be used; we generally...</td>\n",
       "      <td>[{'sacituzumab govitecan'}, {'trastuzumab deru...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>q20</td>\n",
       "      <td>If a bladder cancer patient has FGFR3 mutation...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>The US FDA has approved Erdafitnib for use for...</td>\n",
       "      <td>[{'erdafitinib'}]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Question_index                                             prompt  \\\n",
       "0              q0  What is the first-line treatment of metastatic...   \n",
       "1              q1  Are PARP inhibitors used for patients with lei...   \n",
       "2              q2  Are ALK inhibitors approved for use in TFCP2 f...   \n",
       "3              q3  For a patient with cancer metastatic prostate ...   \n",
       "4              q4  For a patient with HER2+ breast cancer after n...   \n",
       "5              q5  For patients with advanced cancer and with NTR...   \n",
       "6              q6  For patients with advanced cancer and with hig...   \n",
       "7              q7  What FDA-approved therapies exist for a Stage ...   \n",
       "8              q8  What are available FDA-approved targeted thera...   \n",
       "9              q9  A patient with localized Ewing sarcoma has a S...   \n",
       "10            q10  A patient with relapsed high-risk neuroblastom...   \n",
       "11            q11  I have a 3 year old patient with Neuroblastoma...   \n",
       "12            q12  My 20 year old patient with ALK mutated Neurob...   \n",
       "13            q13  For a 17-year-old osteosarcoma patient with 50...   \n",
       "14            q14  Is there an optimal drug combination to minimi...   \n",
       "15            q15  For a 4 year old patient with medulloblastoma,...   \n",
       "16            q16  For toddler with unresectable hepatoblastoma a...   \n",
       "17            q17  I have a patient with de novo metastatic HR+ b...   \n",
       "18            q18  I have a patient with an initial diagnosis of ...   \n",
       "19            q19  I have a patient with metastatic HR-negative, ...   \n",
       "20            q20  If a bladder cancer patient has FGFR3 mutation...   \n",
       "\n",
       "    Asking_therapy  Given_biomarker  \\\n",
       "0             True             True   \n",
       "1             True             True   \n",
       "2             True             True   \n",
       "3             True             True   \n",
       "4             True             True   \n",
       "5             True             True   \n",
       "6             True             True   \n",
       "7             True             True   \n",
       "8             True             True   \n",
       "9             True             True   \n",
       "10            True             True   \n",
       "11            True             True   \n",
       "12            True             True   \n",
       "13            True             True   \n",
       "14            True             True   \n",
       "15            True             True   \n",
       "16            True             True   \n",
       "17            True             True   \n",
       "18            True             True   \n",
       "19            True             True   \n",
       "20            True             True   \n",
       "\n",
       "                                    Question_category  Is_there_an_approval  \\\n",
       "0           given disease and biomarker, return drugs                  True   \n",
       "1           given disease and biomarker, return drugs                 False   \n",
       "2           given disease and biomarker, return drugs                 False   \n",
       "3           given disease and biomarker, return drugs                  True   \n",
       "4   given disease and biomarker, return drugs; HER...                  True   \n",
       "5           given disease and biomarker, return drugs                  True   \n",
       "6           given disease and biomarker, return drugs                  True   \n",
       "7           given disease and biomarker, return drugs                  True   \n",
       "8           given disease and biomarker, return drugs                 False   \n",
       "9           given disease and biomarker, return drugs                 False   \n",
       "10          given disease and biomarker, return drugs                 False   \n",
       "11          given disease and biomarker, return drugs                 False   \n",
       "12          given disease and biomarker, return drugs                 False   \n",
       "13          given disease and biomarker, return drugs                 False   \n",
       "14  given disease and biomarker, return drugs; not...                 False   \n",
       "15          given disease and biomarker, return drugs                 False   \n",
       "16          given disease and biomarker, return drugs                 False   \n",
       "17  given disease and biomarker, return drugs; HER...                  True   \n",
       "18  given disease and biomarker, return drugs; HER...                  True   \n",
       "19  given disease and biomarker, return drugs; not...                  True   \n",
       "20          given disease and biomarker, return drugs                  True   \n",
       "\n",
       "                                  Groundtruth_answers  \\\n",
       "0                                         erdafitinib   \n",
       "1   PARP inhibitors are not yet approved for the t...   \n",
       "2   No, no ALK inhibitors are currently approved f...   \n",
       "3   The following therapy and combination therapie...   \n",
       "4         TDM-1 (ado-trastuzumab emtansine (Kadcyla))   \n",
       "5   Yes, the TRK inhibitors Entrectinib and Larotr...   \n",
       "6   Yes, Keytruda (pembrolizumab) is approved by t...   \n",
       "7   While no drugs are approved for use by the US ...   \n",
       "8   There are not currently approved therapies for...   \n",
       "9   The US FDA has not yet approved any treatments...   \n",
       "10  The US FDA has not yet approved any biomarker-...   \n",
       "11  The US FDA has not yet approved any biomarker-...   \n",
       "12  The US FDA has not yet approved any biomarker-...   \n",
       "13  The US FDA has not yet approved any biomarker-...   \n",
       "14  The US FDA has not yet approved any biomarker-...   \n",
       "15  The US FDA has not yet approved any biomarker-...   \n",
       "16  The US FDA has not yet approved any biomarker-...   \n",
       "17  Two therapeutic hypotheses to consider for thi...   \n",
       "18  While this version of MOAlmanac does not direc...   \n",
       "19  Either T-DXd or SG could be used; we generally...   \n",
       "20  The US FDA has approved Erdafitnib for use for...   \n",
       "\n",
       "                                Groundtruth_therapies  \n",
       "0                                   [{'erdafitinib'}]  \n",
       "1                                                  []  \n",
       "2                                                  []  \n",
       "3   [{'olaparib'}, {'prednisone', 'olaparib', 'abi...  \n",
       "4                     [{'ado-trastuzumab emtansine'}]  \n",
       "5                [{'entrectinib'}, {'larotrectinib'}]  \n",
       "6                                 [{'pembrolizumab'}]  \n",
       "7                [{'entrectinib'}, {'larotrectinib'}]  \n",
       "8                                                  []  \n",
       "9                                                  []  \n",
       "10                                                 []  \n",
       "11                                                 []  \n",
       "12                                                 []  \n",
       "13                                                 []  \n",
       "14                                                 []  \n",
       "15                                                 []  \n",
       "16                                                 []  \n",
       "17  [{'talazoparib'}, {'capivasertib', 'fulvestran...  \n",
       "18  [{'ado-trastuzumab emtansine'}, {'trastuzumab'...  \n",
       "19  [{'sacituzumab govitecan'}, {'trastuzumab deru...  \n",
       "20                                  [{'erdafitinib'}]  "
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "real_questions = pd.read_csv(os.path.join(root_dir, 'data/real_world_queries.csv'), index_col=0)\n",
    "real_questions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load LLM outputs from real-world queries\n",
    "real_rag_res_dict_4=load_object(filename=os.path.join(root_dir, 'output/RAG_res_mistnemo/realworld/RAGstra4n5temp0.0_res_dict.pkl'))\n",
    "real_rag_res_dict_5=load_object(filename=os.path.join(root_dir, 'output/RAG_res_mistnemo/realworld/RAGstra5n5temp0.0_res_dict.pkl'))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Label results from real-world queries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load mapping between real-world queries and ground-truth drugs\n",
    "real_prompt_groundtruth_dict=load_object(os.path.join(root_dir, 'data/real_prompt_groundtruth_dict.pkl'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load results from all runs\n",
    "all_real_results = {\n",
    "    4: {'ragllm_input':[],'ragllm_output':[],'full':[], 'partial':[], 'exact':[], 'avg_partial':[], 'avg_exact':[]},\n",
    "    5: {'ragllm_input':[],'ragllm_output':[],'full':[], 'partial':[], 'exact':[], 'avg_partial':[], 'avg_exact':[]}\n",
    "}\n",
    "\n",
    "for i in range(len(real_rag_res_dict_4['full output'])):\n",
    "    for strategy, output_dict in zip(\n",
    "        [4, 5],\n",
    "        [real_rag_res_dict_4, real_rag_res_dict_5]\n",
    "    ):\n",
    "        res = calc_eval_metrics(output_dict['full output'][i], real_questions['prompt'], real_prompt_groundtruth_dict)\n",
    "        all_real_results[strategy]['ragllm_input'].append(output_dict['input prompt'][i])\n",
    "        all_real_results[strategy]['ragllm_output'].append(output_dict['full output'][i])\n",
    "        all_real_results[strategy]['full'].append(res)\n",
    "        all_real_results[strategy]['partial'].append(res['partial_match_acc'])\n",
    "        all_real_results[strategy]['exact'].append(res['exact_match_acc'])\n",
    "        all_real_results[strategy]['avg_partial'].append(res['avg_partial_match_acc'])\n",
    "        all_real_results[strategy]['avg_exact'].append(res['avg_exact_match_acc'])\n",
    "\n",
    "def make_eval_df(data, prefix):\n",
    "    return pd.DataFrame(data).T.add_prefix(prefix)\n",
    "\n",
    "real_res_stra4_partial_acc_df = make_eval_df(all_real_results[4]['partial'], 'partial_match_acc_')\n",
    "real_res_stra4_exact_acc_df   = make_eval_df(all_real_results[4]['exact'],   'exact_match_acc_')\n",
    "\n",
    "real_res_stra5_partial_acc_df = make_eval_df(all_real_results[5]['partial'], 'partial_match_acc_')\n",
    "real_res_stra5_exact_acc_df   = make_eval_df(all_real_results[5]['exact'],   'exact_match_acc_')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [],
   "source": [
    "def calc_cnt_by_categories(strategy, results_dict, nth_iter, real_questions):\n",
    "\n",
    "    matching_cnt_ls=[]\n",
    "    missing_cnt_ls=[]\n",
    "    hallucinating_cnt_ls=[]\n",
    "    no_output_cnt_ls=[]\n",
    "    \n",
    "    all_true_set_of_subsets=results_dict[strategy]['full'][nth_iter]['true_drugs_generic_set_ls']\n",
    "    all_pred_set_of_subsets=results_dict[strategy]['full'][nth_iter]['pred_drugs_generic_set_ls']\n",
    "\n",
    "    for i in range(len(real_questions)):\n",
    "        true_set_of_subsets = all_true_set_of_subsets[i]\n",
    "        pred_set_of_subsets = all_pred_set_of_subsets[i]\n",
    "\n",
    "        matching_cnt=len(pred_set_of_subsets.intersection(true_set_of_subsets))\n",
    "        missing_cnt=len(true_set_of_subsets - pred_set_of_subsets)\n",
    "        hallucinating_cnt=len(pred_set_of_subsets - true_set_of_subsets)\n",
    "        no_output_cnt=1 if len(pred_set_of_subsets) == 0 else 0\n",
    "\n",
    "        matching_cnt_ls.append(matching_cnt)\n",
    "        missing_cnt_ls.append(missing_cnt)\n",
    "        hallucinating_cnt_ls.append(hallucinating_cnt)\n",
    "        no_output_cnt_ls.append(no_output_cnt)\n",
    "\n",
    "    res_df=pd.DataFrame({\n",
    "        'matching_cnt':matching_cnt_ls,\n",
    "        'missing_cnt':missing_cnt_ls,\n",
    "        'hallucinating_cnt':hallucinating_cnt_ls,\n",
    "        'no_output_cnt':no_output_cnt_ls\n",
    "        })\n",
    "    \n",
    "    res_df=pd.concat([real_questions, res_df], axis=1)\n",
    "\n",
    "    return(res_df)\n",
    "\n",
    "real_rag_res_cnt_df_4 = calc_cnt_by_categories(\n",
    "    strategy=4, \n",
    "    results_dict=all_real_results, \n",
    "    nth_iter=0, \n",
    "    real_questions=real_questions)\n",
    "\n",
    "real_rag_res_cnt_df_5 = calc_cnt_by_categories(\n",
    "    strategy=5, \n",
    "    results_dict=all_real_results, \n",
    "    nth_iter=0, \n",
    "    real_questions=real_questions)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Plot stacked bar plot"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The result from the first iteration was used for the calculation of matching, missing, hallucinating, and no output counts."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 400x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Convert to DataFrame\n",
    "df = pd.DataFrame(real_rag_res_cnt_df_4\n",
    "[['Question_index','matching_cnt','missing_cnt','hallucinating_cnt','no_output_cnt']])\n",
    "\n",
    "# Add a 'Total' column to sort by\n",
    "df['total'] = df['matching_cnt'] + df['missing_cnt'] + df['hallucinating_cnt'] + df['no_output_cnt']\n",
    "\n",
    "# Sort by the 'Total' column\n",
    "df_sorted = df.sort_values('total', ascending=True)\n",
    "\n",
    "# Stacked Bar Plot\n",
    "fig, ax = plt.subplots(figsize=(4, 5))\n",
    "df_sorted.set_index(\"Question_index\")[['matching_cnt', 'missing_cnt', 'hallucinating_cnt', 'no_output_cnt']].plot(kind=\"barh\", stacked=True, color=[\"green\", \"red\", \"orange\", \"grey\"], ax=ax)\n",
    "\n",
    "# Set axes background color\n",
    "ax.set_facecolor('white') \n",
    "\n",
    "# Change background grid color\n",
    "ax.grid(visible=True, axis='x', color='lightgray', linestyle='--')\n",
    "\n",
    "# Labels\n",
    "plt.xlabel(\"Number of Therapies\")\n",
    "plt.ylabel(\"Questions\")\n",
    "plt.xticks(rotation=0)\n",
    "plt.legend([\"Matched\", \"Missing\", \"Hallucinating\",\"No drugs\"], loc='lower right')\n",
    "\n",
    "# Save\n",
    "save = True\n",
    "if save == True:\n",
    "    plt.savefig('./figures/Figure4_realquestions_stackedbar_1.jpeg', dpi=500, bbox_inches='tight')\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 400x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Convert to DataFrame\n",
    "df = pd.DataFrame(real_rag_res_cnt_df_5[['Question_index','matching_cnt','missing_cnt','hallucinating_cnt','no_output_cnt']])\n",
    "\n",
    "# Add a 'Total' column to sort by\n",
    "df['total'] = df['matching_cnt'] + df['missing_cnt'] + df['hallucinating_cnt'] + df['no_output_cnt']\n",
    "\n",
    "# Sort by the 'Total' column\n",
    "df_sorted = df.sort_values('total', ascending=True)\n",
    "\n",
    "# Stacked Bar Plot\n",
    "fig, ax = plt.subplots(figsize=(4, 5))\n",
    "df_sorted.set_index(\"Question_index\")[['matching_cnt', 'missing_cnt', 'hallucinating_cnt', 'no_output_cnt']].plot(kind=\"barh\", stacked=True, color=[\"green\", \"red\", \"orange\", \"grey\"], ax=ax)\n",
    "\n",
    "# Set axes background color\n",
    "ax.set_facecolor('white')\n",
    "\n",
    "# Change background grid color\n",
    "ax.grid(visible=True, axis='x', color='lightgray', linestyle='--')\n",
    "\n",
    "# Labels\n",
    "plt.xlabel(\"Number of Therapies\")\n",
    "plt.ylabel(\"Questions\")\n",
    "plt.xticks(rotation=0)\n",
    "plt.legend([\"Matched\", \"Missing\", \"Hallucinating\",\"No drugs\"], loc='lower right')\n",
    "\n",
    "# Save\n",
    "save = True\n",
    "if save == True:\n",
    "    plt.savefig('./figures/Figure4_realquestions_stackedbar_2.jpeg', dpi=500, bbox_inches='tight')\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 4C. Accuracies of RAG-LLM based on structured data on real-world questions"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Plot bar graph"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 450x370 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# compute means and standard deviations\n",
    "means = {\n",
    "    'Structured RAG-LLM \\n(without out-of-scope instruction)': \n",
    "        [np.mean(all_real_results[4]['avg_exact']) * 100, np.mean(all_real_results[4]['avg_partial']) * 100],\n",
    "    'Structured RAG-LLM \\n(with out-of-scope instruction)': \n",
    "        [np.mean(all_real_results[5]['avg_exact']) * 100, np.mean(all_real_results[5]['avg_partial']) * 100]\n",
    "}\n",
    "\n",
    "stds = {\n",
    "    'Structured RAG-LLM \\n(without out-of-scope instruction)': \n",
    "        [np.std(all_real_results[4]['avg_exact']) * 100, np.std(all_real_results[4]['avg_partial']) * 100],\n",
    "    'Structured RAG-LLM \\n(with out-of-scope instruction)': \n",
    "        [np.std(all_real_results[5]['avg_exact']) * 100, np.std(all_real_results[5]['avg_partial']) * 100]\n",
    "}\n",
    "\n",
    "# convert to dataframe\n",
    "plot_res = pd.DataFrame(means, index=['Exact match accuracy','Partial match accuracy'])\n",
    "\n",
    "# Convert stds to DataFrame for error bars\n",
    "error_bars = pd.DataFrame(stds, index=['Exact match accuracy','Partial match accuracy'])\n",
    "\n",
    "# set figure size\n",
    "plt.rcParams[\"figure.figsize\"] = [4.5, 3.7]\n",
    "\n",
    "# set color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# create a mapping of rownames to colors\n",
    "row_colors = dict(zip(plot_res.columns, [cols[7],cols[8]]))\n",
    "\n",
    "# create bar plot\n",
    "ax=plot_res.plot(kind='bar', \n",
    "                 yerr=error_bars,\n",
    "                 capsize=4,\n",
    "                 color=[row_colors[name] for name in plot_res.columns], \n",
    "                 width=0.6, \n",
    "                 legend=False\n",
    "                 )\n",
    "\n",
    "# add text\n",
    "for bar in ax.patches:\n",
    "    x = bar.get_x() + bar.get_width() / 2\n",
    "    y = bar.get_height()\n",
    "    ax.text(x, 1, f'{y:.2f}', ha='center', va='bottom', fontsize=10, color='black')\n",
    "    \n",
    "# x, y labels, ticks, grid\n",
    "ax.set_xlabel('')\n",
    "ax.set_ylabel('Accuracy (%)', fontsize=12)\n",
    "ax.tick_params(axis='x', labelsize=9, rotation=0)\n",
    "ax.tick_params(axis='y', labelsize=10)\n",
    "ax.set_facecolor(color='white')\n",
    "\n",
    "# remove border\n",
    "for spine in ax.spines.values():\n",
    "    spine.set_visible(False)\n",
    "    \n",
    "# set alpha for the rest of the bars\n",
    "for i, patch in enumerate(ax.patches):\n",
    "    patch.set_alpha(0.6)\n",
    "\n",
    "# Create a custom legend\n",
    "handles = [plt.Rectangle((0,0),1,1, color=row_colors[name]) for name in plot_res.columns]\n",
    "legend = ax.legend(handles, plot_res.columns, \n",
    "          title=False, \n",
    "          bbox_to_anchor=(0.5, -0.12), ncol=2,\n",
    "          frameon=False,\n",
    "          borderaxespad=1,\n",
    "          loc='upper center',\n",
    "          fontsize=9,\n",
    "          title_fontsize=9\n",
    "          ) \n",
    "legend.get_frame().set_facecolor('white')\n",
    "\n",
    "# save\n",
    "save = True\n",
    "if save == True:\n",
    "    plt.savefig('./figures/Figure4_realworld_accuracyRAGLLMbar.jpeg', dpi=500, bbox_inches='tight')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Run McNemar's Test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create contingency table\n",
    "exact_table_ls=[]\n",
    "partial_table_ls=[]\n",
    "\n",
    "for i in range(5):\n",
    "    exact_table_ls.append(create_mcnemar_table(\n",
    "        all_real_results[4]['exact'][i], \n",
    "        all_real_results[5]['exact'][i]\n",
    "        )\n",
    "                          )\n",
    "    \n",
    "    partial_table_ls.append(create_mcnemar_table(\n",
    "        all_real_results[4]['partial'][i], \n",
    "        all_real_results[5]['partial'][i]\n",
    "        )\n",
    "                            )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[0.001953125, 0.00390625, 0.001953125, 0.0009765625, 0.001953125]\n",
      "[0.001953125, 0.00390625, 0.001953125, 0.0009765625, 0.001953125]\n",
      "[0.00244141 0.00390625 0.00244141 0.00244141 0.00244141]\n",
      "[0.00244141 0.00390625 0.00244141 0.00244141 0.00244141]\n"
     ]
    }
   ],
   "source": [
    "# Perform McNemar's test\n",
    "exact_result_ls=[]\n",
    "partial_result_ls=[]\n",
    "exact_result_pval=[]\n",
    "partial_result_pval=[]\n",
    "\n",
    "for i in range(5):\n",
    "    exact_result_ls.append(conduct_mcnemar_test(exact_table_ls[i]))\n",
    "    partial_result_ls.append(conduct_mcnemar_test(partial_table_ls[i]))\n",
    "    \n",
    "    exact_result_pval.append(exact_result_ls[i].pvalue)\n",
    "    partial_result_pval.append(partial_result_ls[i].pvalue)\n",
    "\n",
    "# Perform multiple test correction\n",
    "from statsmodels.stats.multitest import multipletests\n",
    "\n",
    "rejected, exact_pval_corrected, _, _ = multipletests(exact_result_pval, alpha=0.05, method='fdr_bh')\n",
    "rejected, partial_pval_corrected, _, _ = multipletests(partial_result_pval, alpha=0.05, method='fdr_bh')\n",
    "\n",
    "print(exact_result_pval)\n",
    "print(partial_result_pval)\n",
    "print(exact_pval_corrected)\n",
    "print(partial_pval_corrected)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Calculate mean precision, recall, F1 score"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Avg Precision: 95.0000\n",
      "Avg Recall: 78.5758\n",
      "Avg F1: 80.5000\n"
     ]
    }
   ],
   "source": [
    "def compute_metric_mean(metric_name, results_dict, strategy, idx_list, n_runs: int=5) -> float:\n",
    "    \"\"\"Compute the mean of a metric over selected questions (e.g. with on-label FDA-approved drugs) across multiple runs\"\"\"\n",
    "    means = []\n",
    "    for x in range(n_runs):\n",
    "        values = [\n",
    "            val for i, val in enumerate(results_dict[strategy]['full'][x][metric_name])\n",
    "            if i in idx_list\n",
    "        ]\n",
    "        means.append(np.mean(values))\n",
    "    return np.mean(means)\n",
    "\n",
    "fda_questions_idx = real_questions[real_questions['Is_there_an_approval'] == True].index\n",
    "\n",
    "for metric in ['precision_ls','recall_ls','f1_ls']:\n",
    "    avg = compute_metric_mean(\n",
    "        metric_name=metric,\n",
    "        results_dict=all_real_results,\n",
    "        strategy=5,\n",
    "        idx_list=fda_questions_idx\n",
    "        )\n",
    "    print(f\"Avg {metric.replace('_ls','').capitalize()}: {avg*100:.4f}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Supplementary Note 1-2. Example of synthetic prompt and output from RAG-LLM "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Unstructured version"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['INDICATIONS AND USAGE  --------------------------  \\nLynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: \\nOvarian cancer \\n• for the maintenance treatment of adult patients with deleterious or \\nsuspected deleterious germline or somatic BRCA-mutated advanced \\nepithelial ovarian, fallopian tube or primary peritoneal cancer who are in \\ncomplete or partial response to first-line platinum-based chemotherapy. \\nSelect patients for therapy based on an FDA-approved companion \\ndiagnostic for Lynparza. (1.1, 2.1) \\n• in combination with bevacizumab for the maintenance treatment of adult \\npatients with advanced epithelial ovarian, fallopian tube or primary \\nperitoneal cancer who are in complete or partial response to first-line \\nplatinum-based chemotherapy and whose cancer is associated with \\nhomologous recombination deficiency (HRD)-positive status defined by \\neither: \\n• a deleterious or suspected deleterious BRCA mutation, and/or  \\n• genomic instability.  \\nSelect patients for therapy based on an FDA-approved companion \\ndiagnostic for Lynparza (1.2, 2.1). \\n• for the maintenance treatment of adult patients with recurrent epithelial \\novarian, fallopian tube or primary peritoneal cancer, who are in \\ncomplete or partial response to platinum-based chemotherapy. (1.3) \\nBreast cancer \\n• for the adjuvant treatment of adult patients with deleterious or suspected \\ndeleterious gBRCAm human epidermal growth factor receptor 2 \\n(HER2)-negative high risk early breast cancer who have been treated \\nwith neoadjuvant or adjuvant chemotherapy. Select patients for therapy \\nbased on an FDA-approved companion diagnostic for Lynparza. (1.4, \\n2.1). \\n• for the treatment of adult patients with deleterious or suspected \\ndeleterious gBRCAm, HER2-negative metastatic breast cancer who have \\nbeen treated with chemotherapy in the neoadjuvant, adjuvant or \\nmetastatic setting. Patients with hormone receptor (HR)-positive breast \\ncancer should have been treated with a prior endocrine therapy or be \\nconsidered inappropriate for endocrine therapy. Select patients for \\ntherapy based on an FDA-approved companion diagnostic for Lynparza. \\n(1.5, 2.1) \\nPancreatic cancer \\n• for the maintenance treatment of adult patients with deleterious or \\nsuspected deleterious gBRCAm metastatic pancreatic adenocarcinoma \\nwhose disease has not progressed on at least 16 weeks of a first-line \\nplatinum-based chemotherapy regimen. Select patients for therapy based \\non an FDA-approved companion diagnostic for Lynparza. (1.6, 2.1) \\nProstate cancer \\n• for the treatment of adult patients with deleterious or suspected \\ndeleterious germline or somatic homologous recombination repair \\n(HRR) gene-mutated metastatic castration-resistant prostate cancer \\n(mCRPC) who have progressed following prior treatment with \\nenzalutamide or abiraterone. Select patients for therapy based on an \\nFDA-approved companion diagnostic for Lynparza. (1.7, 2.1) \\n• in combination with abiraterone and prednisone or prednisolone for the \\ntreatment of adult patients with deleterious or suspected deleterious \\nBRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer \\n(mCRPC). Select patients for therapy based on an FDA-approved \\ncompanion diagnostic for Lynparza. (1.8, 2.1) \\n ----------------------', 'INDICATIONS AND USAGE---------------------------\\xad\\nRUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: \\nOvarian cancer \\n•\\t for the maintenance treatment of adult patients with recurrent epithelial \\novarian, fallopian tube, or primary peritoneal cancer who are in a complete \\nor partial response to platinum-based chemotherapy. (1.1) \\n•\\t for the treatment of adult patients with a deleterious BRCA mutation \\n(germline and/or somatic)-associated epithelial ovarian, fallopian tube, or \\nprimary peritoneal cancer who have been treated with two or more \\nchemotherapies. Select patients for therapy based on an FDA-approved \\ncompanion diagnostic for RUBRACA. (1.1, 2.1) \\nProstate cancer \\n•\\t for the treatment of adult patients with a deleterious BRCA mutation \\n(germline and/or somatic)-associated metastatic castration-resistant prostate \\ncancer (mCRPC) who have been treated with androgen receptor-directed \\ntherapy and a taxane-based chemotherapy. Select patients for therapy based \\non an FDA-approved companion diagnostic for RUBRACA. (1.2, 2.1) \\nThis indication is approved under accelerated approval based on objective \\nresponse rate and duration of response. Continued approval for this \\nindication may be contingent upon verification and description of clinical \\nbenefit in confirmatory trials. (1.2) \\n-----------------------', 'INDICATIONS AND USAGE \\nZEJULA is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated: \\n\\uf0b7 for the maintenance treatment of adult patients with advanced \\nepithelial ovarian, fallopian tube, or primary peritoneal cancer who \\nare in a complete or partial response to first-line platinum-based \\nchemotherapy. (1.1) \\n\\uf0b7 for the maintenance treatment of adult patients with recurrent \\nepithelial ovarian, fallopian tube, or primary peritoneal cancer who \\nare in a complete or partial response to platinum-based \\nchemotherapy. (1.2) \\n\\uf0b7 for the treatment of adult patients with advanced ovarian, fallopian \\ntube, or primary peritoneal cancer who have been treated with three \\nor more prior chemotherapy regimens and whose cancer is \\nassociated with homologous recombination deficiency (HRD) \\npositive status defined by either: \\n\\uf0b7\\t a deleterious or suspected deleterious BRCA mutation, or \\n\\uf0b7\\t genomic instability and who have progressed more than six \\nmonths after response to the last platinum-based \\nchemotherapy. \\nSelect patients for therapy based on an FDA-approved companion \\ndiagnostic for ZEJULA. (1.3, 2.1)', 'INDICATIONS AND USAGE----------------------------\\nTALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated \\nfor: \\nBreast Cancer \\n• As a single agent, for the treatment of adult patients with deleterious or \\nsuspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative \\nlocally advanced or metastatic breast cancer. Select patients for therapy \\nbased on an FDA-approved companion diagnostic for TALZENNA. (1.1) \\nHRR Gene-mutated mCRPC \\n• In combination with enzalutamide for the treatment of adult patients with \\nHRR gene-mutated metastatic castration-resistant prostate cancer \\n(mCRPC). (1.2) \\n----------------------', 'INDICATIONS AND USAGE---------------------------\\nAKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase \\n(PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with \\nprednisone for the treatment of adult patients with deleterious or suspected \\ndeleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate \\ncancer (mCRPC). Select patients for therapy based on an FDA-approved test \\nfor AKEEGA. (1, 2.1) \\n------------------------', 'INDICATIONS AND USAGE-------------------------\\xad\\nPIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the \\ntreatment of postmenopausal women, and men, with hormone receptor (HR)\\xad\\npositive, human epidermal growth factor receptor 2 (HER2)-negative, \\nPIK3CA-mutated, advanced or metastatic breast cancer as detected by an \\nFDA-approved test following progression on or after an endocrine-based \\nregimen. (1) \\n----------------------', 'INDICATIONS AND USAGE -------------------------\\xad\\nSTIVARGA is a kinase inhibitor indicated for the treatment of patients with: \\n• Metastatic colorectal cancer (CRC) who have been previously treated with \\nfluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-\\nVEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. (1.1) \\n• Locally advanced, unresectable or metastatic gastrointestinal stromal tumor \\n(GIST) who have been previously treated with imatinib mesylate and \\nsunitinib malate. (1.2) \\n• Hepatocellular carcinoma (HCC) who have been previously treated with \\nsorafenib (1.3) \\n----------------------', 'INDICATIONS AND USAGE\\uf8e7\\uf8e7\\uf8e7\\uf8e7\\uf8e7\\uf8e7\\uf8e7\\uf8e7\\uf8e7 \\nKADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate \\nindicated, as a single agent, for: \\n•\\t the treatment of patients with HER2-positive, metastatic breast cancer \\nwho previously received trastuzumab and a taxane, separately or in \\ncombination. Patients should have either: \\n•\\t received prior therapy for metastatic disease, or \\n•\\t developed disease recurrence during or within six months of \\ncompleting adjuvant therapy. (1.1) \\n•\\t the adjuvant treatment of patients with HER2-positive early breast cancer \\nwho have residual invasive disease after neoadjuvant taxane and \\ntrastuzumab-based treatment. (1.2) \\nSelect patients for therapy based on an FDA-approved companion diagnostic \\nfor KADCYLA [see Dosage and Administration (2.1)] \\n\\uf8e7\\uf8e7\\uf8e7\\uf8e7\\uf8e7\\uf8e7\\uf8e7', 'INDICATIONS AND USAGE --------------------------\\nTRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for \\nthe treatment of adult patients with hormone receptor (HR)-positive, human \\nepidermal growth factor receptor 2 (HER2)-negative, locally advanced or \\nmetastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as \\ndetected by an FDA-approved test following progression on at least one \\nendocrine-based regimen in the metastatic setting or recurrence on or within \\n12 months of completing adjuvant therapy. (1) \\n----------------------', 'INDICATIONS AND USAGE--------------------------\\xad\\nLUMAKRAS is an inhibitor of the RAS GTPase family indicated for the \\ntreatment of adult patients with KRAS G12C-mutated locally advanced or \\nmetastatic non-small cell lung cancer (NSCLC), as determined by an \\nFDA-approved test, who have received at least one prior systemic therapy. (1) \\nThis indication is approved under accelerated approval based on overall \\nresponse rate (ORR) and duration of response (DOR). Continued approval for \\nthis indication may be contingent upon verification and description of clinical \\nbenefit in a confirmatory trial(s). (1) \\n----------------------']\n",
      "    ---------------------\n",
      "    \n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "        {\n",
      "            \"Treatment 1\": {\n",
      "                \"Disease Name\": ,\n",
      "                \"Disease Phase or Condition\": ,\n",
      "                \"Drug Name\": ,\n",
      "                \"Prior Treatment or Resistance Status\": ,\n",
      "                \"Genomic Features\":\n",
      "                \"Link to FDA-approved Label\": \n",
      "                }\n",
      "        }\n",
      "        Query: If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, what would be the suggested lines of treatment?\n",
      "         \n",
      "    \n"
     ]
    }
   ],
   "source": [
    "# Input prompt\n",
    "print(rag_unstruc_res_dict_0['input prompt'][0][180])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n",
      "    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n",
      "    \"Drug Name\": \"Lynparza\",\n",
      "    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n",
      "    \"Genomic Features\": \"Somatic variant in gene BRCA1\",\n",
      "    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213545s000lbl.pdf\"\n",
      "  },\n",
      "  \"Treatment 2\": {\n",
      "    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n",
      "    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n",
      "    \"Drug Name\": \"Rubraca\",\n",
      "    \"Prior Treatment or Resistance Status\": \"Treated with androgen receptor-directed therapy and a taxane-based chemotherapy\",\n",
      "    \"Genomic Features\": \"Somatic variant in gene BRCA1\",\n",
      "    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211132s000lbl.pdf\"\n",
      "  },\n",
      "  \"Treatment 3\": {\n",
      "    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n",
      "    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n",
      "    \"Drug Name\": \"Akeega (niraparib + abiraterone acetate)\",\n",
      "    \"Prior Treatment or Resistance Status\": \"Not specified in the given label\",\n",
      "    \"Genomic Features\": \"Somatic variant in gene BRCA1\",\n",
      "    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213666s000lbl.pdf\"\n",
      "  }\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "# RAG-LLM response\n",
    "print(rag_unstruc_res_dict_0['full output'][0][180])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Structured version"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CHEK1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CHEK2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n",
      "    ---------------------\n",
      "    \n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "        {\n",
      "            \"Treatment 1\": {\n",
      "                \"Disease Name\": ,\n",
      "                \"Disease Phase or Condition\": ,\n",
      "                \"Drug Name\": ,\n",
      "                \"Prior Treatment or Resistance Status\": ,\n",
      "                \"Genomic Features\":\n",
      "                \"Link to FDA-approved Label\": \n",
      "                }\n",
      "        }\n",
      "        Query: If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, what would be the suggested lines of treatment?\n",
      "         \n",
      "    \n"
     ]
    }
   ],
   "source": [
    "# Input prompt\n",
    "print(rag_struc_res_dict_0['input prompt'][0][180])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Prostate Cancer\",\n",
      "    \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "    \"Drug Name\": \"Olaparib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n",
      "    \"Genomic Features\": \"Somatic variant in gene BRCA1\",\n",
      "    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "  },\n",
      "  \"Treatment 2\": {\n",
      "    \"Disease Name\": \"Prostate Cancer\",\n",
      "    \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "    \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "    \"Genomic Features\": \"Somatic variant in gene BRCA1\",\n",
      "    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "  }\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "# RAG-LLM response \n",
    "print(rag_struc_res_dict_0['full output'][0][180])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Supplementary Note 3. Example real-world query without FDA-approved drugs available"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).']\n",
      "    ---------------------\n",
      "    \n",
      "        If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n",
      "        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n",
      "        {\n",
      "            \"Treatment 1\": {\n",
      "                \"Disease Name\": ,\n",
      "                \"Disease Phase or Condition\": ,\n",
      "                \"Drug Name\": ,\n",
      "                \"Prior Treatment or Resistance Status\": ,\n",
      "                \"Genomic Features\": \n",
      "                \"FDA-approval status\":\n",
      "                \"Link to FDA-approved Label\":\n",
      "                }\n",
      "        }\n",
      "        Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n",
      "         \n",
      "    \n"
     ]
    }
   ],
   "source": [
    "# An example of real-world expert query without FDA-approved drugs available\n",
    "i=2\n",
    "print(real_rag_res_dict_4['input prompt'][0][i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Rhabdomyosarcoma\",\n",
      "    \"Disease Phase or Condition\": \"Metastatic or unresectable\",\n",
      "    \"Drug Name\": \"Crizotinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"No prior treatment or resistant to prior treatment\",\n",
      "    \"Genomic Features\": \"ALK (Anaplastic Lymphoma Kinase) fusion (TFCP2-ALK)\",\n",
      "    \"FDA-approval status\": \"Not explicitly approved for rhabdomyosarcoma, but approved for ALK-positive solid tumors\",\n",
      "    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n",
      "  }\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "# Full RAG-LLM's response from the corresponding real-world query\n",
    "print(real_rag_res_dict_4['full output'][0][i])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Merge real-world results for supplementary table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def create_selected_output_df(all_results_dict, selected_output, column_prefix):\n",
    "    df = pd.DataFrame.from_dict(all_results_dict[selected_output]).T\n",
    "    df = df.add_prefix(column_prefix)\n",
    "    return(df)\n",
    "\n",
    "strategy=5\n",
    "input_df=create_selected_output_df(all_real_results[strategy], 'ragllm_input', 'RAGLLM_input_prompt_')\n",
    "full_output_df=create_selected_output_df(all_real_results[strategy], 'ragllm_output', 'RAGLLM_full_output_')\n",
    "\n",
    "pred_drug_output_ls = list()\n",
    "for i in range(len(all_real_results[strategy]['full'])):\n",
    "    pred_drug_output_ls.append(all_real_results[strategy]['full'][i]['pred_drugs_generic_set_ls'])\n",
    "\n",
    "drug_output_df=pd.DataFrame(pred_drug_output_ls).T.add_prefix('RAGLLM_drug_output_')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 157,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Question_index",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "prompt",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Asking_therapy",
         "rawType": "bool",
         "type": "boolean"
        },
        {
         "name": "Given_biomarker",
         "rawType": "bool",
         "type": "boolean"
        },
        {
         "name": "Question_category",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Is_there_an_approval",
         "rawType": "bool",
         "type": "boolean"
        },
        {
         "name": "Groundtruth_answers",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Groundtruth_therapies",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "matching_cnt",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "missing_cnt",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "hallucinating_cnt",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "no_output_cnt",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "RAGLLM_drug_output_0",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "RAGLLM_drug_output_1",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "RAGLLM_drug_output_2",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "RAGLLM_drug_output_3",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "RAGLLM_drug_output_4",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "RAGLLM_full_output_0",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_full_output_1",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_full_output_2",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_full_output_3",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_full_output_4",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_input_prompt_0",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_input_prompt_1",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_input_prompt_2",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_input_prompt_3",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_input_prompt_4",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "8ca5fdf2-f3ab-4dd0-a132-56e5ad3d93c6",
       "rows": [
        [
         "0",
         "q0",
         "What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? ",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "erdafitinib",
         "[{'erdafitinib'}]",
         "1",
         "0",
         "0",
         "0",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic Urothelial Carcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic, progressed during or following at least one line of prior platinum containing chemotherapy\",\n    \"Drug Name\": \"Erdafitinib\",\n    \"Prior Treatment or Resistance Status\": \"Has received prior PD-1 or PD-L1 inhibitor therapy\",\n    \"Genomic Features\": \"FGFR3 S249C mutation (c.746C>G)\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA)\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic Urothelial Carcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic, progressed during or following at least one line of prior platinum containing chemotherapy\",\n    \"Drug Name\": \"Erdafitinib\",\n    \"Prior Treatment or Resistance Status\": \"Eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy\",\n    \"Genomic Features\": \"FGFR3 S249C mutation (c.746C>G)\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic.\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic Urothelial Carcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic, progressed during or following at least one line of prior platinum containing chemotherapy\",\n    \"Drug Name\": \"Erdafitinib\",\n    \"Prior Treatment or Resistance Status\": \"Eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy\",\n    \"Genomic Features\": \"FGFR3 S249C mutation (c.746C>G)\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic.\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic Urothelial Carcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic, progressed during or following at least one line of prior platinum containing chemotherapy\",\n    \"Drug Name\": \"Erdafitinib\",\n    \"Prior Treatment or Resistance Status\": \"Eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy\",\n    \"Genomic Features\": \"FGFR3 S249C mutation (c.746C>G)\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic.\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic Urothelial Carcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic, progressed during or following at least one line of prior platinum containing chemotherapy\",\n    \"Drug Name\": \"Erdafitinib\",\n    \"Prior Treatment or Resistance Status\": \"Eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy\",\n    \"Genomic Features\": \"FGFR3 S249C mutation (c.746C>G)\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic.\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n  }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? \n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? \n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? \n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? \n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? \n         \n    "
        ],
        [
         "1",
         "q1",
         "Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "PARP inhibitors are not yet approved for the treatment of patients with leimyosarcoma with mutations in DNA repair pathway genes.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene ATM, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CHEK1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CHEK2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene ATM, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CHEK1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CHEK2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene ATM, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CHEK1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CHEK2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene ATM, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CHEK1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CHEK2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene ATM, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CHEK1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CHEK2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n         \n    "
        ],
        [
         "2",
         "q2",
         "Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "No, no ALK inhibitors are currently approved for use for the treatment of patients with rhabdomyosarcoma, nevermind TFCP2 fusion positive rhabdomyosarcoma.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n         \n    "
        ],
        [
         "3",
         "q3",
         "For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "The following therapy and combination therapies are approved by the US FDA for use for the treatment of patients with BRCA2 mutated metastatic castration resistant prostate cancer: olaparib; abiraterone, olaparib, and prednisone; enzalutamide and talazoparib; abiraterone acetate and niraparib; and rucaparib.",
         "[{'olaparib'}, {'prednisone', 'olaparib', 'abiraterone'}, {'talazoparib', 'enzalutamide'}, {'abiraterone acetate', 'niraparib'}, {'rucaparib'}]",
         "3",
         "2",
         "0",
         "0",
         "{frozenset({'olaparib'}), frozenset({'enzalutamide', 'talazoparib'}), frozenset({'abiraterone', 'prednisone', 'olaparib'})}",
         "{frozenset({'olaparib'}), frozenset({'enzalutamide', 'talazoparib'}), frozenset({'abiraterone', 'prednisone', 'olaparib'})}",
         "{frozenset({'olaparib'}), frozenset({'enzalutamide', 'talazoparib'}), frozenset({'abiraterone', 'prednisone', 'olaparib'})}",
         "{frozenset({'olaparib'}), frozenset({'enzalutamide', 'talazoparib'}), frozenset({'abiraterone', 'prednisone', 'olaparib'})}",
         "{frozenset({'olaparib'}), frozenset({'enzalutamide', 'talazoparib'}), frozenset({'abiraterone', 'prednisone', 'olaparib'})}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n    \"Drug Name\": \"Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n    \"Genomic Features\": \"Somatic variant in gene BRCA2\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated mCRPC\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n    \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"N/A\",\n    \"Genomic Features\": \"Somatic variant in gene BRCA2\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) mCRPC\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  },\n  \"Treatment 3\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n    \"Drug Name\": \"Enzalutamide + Talazoparib\",\n    \"Prior Treatment or Resistance Status\": \"N/A\",\n    \"Genomic Features\": \"Somatic variant in gene BRCA2\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for adult patients with HRR gene-mutated mCRPC\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n    \"Drug Name\": \"Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n    \"Genomic Features\": \"Somatic variant in gene BRCA2\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated mCRPC\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n    \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"N/A\",\n    \"Genomic Features\": \"Somatic variant in gene BRCA2\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) mCRPC\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  },\n  \"Treatment 3\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n    \"Drug Name\": \"Enzalutamide + Talazoparib\",\n    \"Prior Treatment or Resistance Status\": \"N/A\",\n    \"Genomic Features\": \"Somatic variant in gene BRCA2\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for adult patients with HRR gene-mutated mCRPC\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n    \"Drug Name\": \"Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n    \"Genomic Features\": \"Somatic variant in gene BRCA2\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated mCRPC\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n    \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"N/A\",\n    \"Genomic Features\": \"Somatic variant in gene BRCA2\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) mCRPC\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  },\n  \"Treatment 3\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n    \"Drug Name\": \"Enzalutamide + Talazoparib\",\n    \"Prior Treatment or Resistance Status\": \"N/A\",\n    \"Genomic Features\": \"Somatic variant in gene BRCA2\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with HRR gene-mutated mCRPC\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n    \"Drug Name\": \"Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n    \"Genomic Features\": \"Somatic variant in gene BRCA2\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated mCRPC\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n    \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"N/A\",\n    \"Genomic Features\": \"Somatic variant in gene BRCA2\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) mCRPC\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  },\n  \"Treatment 3\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n    \"Drug Name\": \"Enzalutamide + Talazoparib\",\n    \"Prior Treatment or Resistance Status\": \"N/A\",\n    \"Genomic Features\": \"Somatic variant in gene BRCA2\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for adult patients with HRR gene-mutated mCRPC\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n    \"Drug Name\": \"Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n    \"Genomic Features\": \"Somatic variant in gene BRCA2\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated mCRPC\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n    \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"N/A\",\n    \"Genomic Features\": \"Somatic variant in gene BRCA2\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) mCRPC\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  },\n  \"Treatment 3\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n    \"Disease Phase or Condition\": \"Metastatic, Castration-Resistant\",\n    \"Drug Name\": \"Enzalutamide + Talazoparib\",\n    \"Prior Treatment or Resistance Status\": \"N/A\",\n    \"Genomic Features\": \"Somatic variant in gene BRCA2\",\n    \"FDA-approval status\": \"Approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with HRR gene-mutated mCRPC\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf\"\n  }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n         \n    "
        ],
        [
         "4",
         "q4",
         "For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?",
         "True",
         "True",
         "given disease and biomarker, return drugs; HER2-related",
         "True",
         "TDM-1 (ado-trastuzumab emtansine (Kadcyla))",
         "[{'ado-trastuzumab emtansine'}]",
         "1",
         "0",
         "1",
         "0",
         "{frozenset({'docetaxel', 'trastuzumab', 'pertuzumab'}), frozenset({'ado-trastuzumab emtansine'})}",
         "{frozenset({'docetaxel', 'trastuzumab', 'pertuzumab'}), frozenset({'ado-trastuzumab emtansine'})}",
         "{frozenset({'docetaxel', 'trastuzumab', 'pertuzumab'}), frozenset({'ado-trastuzumab emtansine'})}",
         "{frozenset({'docetaxel', 'trastuzumab', 'pertuzumab'}), frozenset({'ado-trastuzumab emtansine'})}",
         "{frozenset({'docetaxel', 'trastuzumab', 'pertuzumab'}), frozenset({'ado-trastuzumab emtansine'})}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy + trastuzumab then surgery\",\n    \"Drug Name\": \"Ado-Trastuzumab Emtansine (T-DM1)\",\n    \"Prior Treatment or Resistance Status\": \"Previously treated with trastuzumab and a taxane, separately or in combination\",\n    \"Genomic Features\": \"HER2-positive\",\n    \"FDA-approval status\": \"Approved as a single agent for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy + trastuzumab then surgery\",\n    \"Drug Name\": \"Pertuzumab + Trastuzumab + Docetaxel\",\n    \"Prior Treatment or Resistance Status\": \"Not previously treated with anti-HER2 therapy or chemotherapy for metastatic disease\",\n    \"Genomic Features\": \"HER2-positive\",\n    \"FDA-approval status\": \"Approved for treatment of patients with HER2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy + trastuzumab then surgery\",\n    \"Drug Name\": \"Ado-Trastuzumab Emtansine (T-DM1)\",\n    \"Prior Treatment or Resistance Status\": \"Previously treated with trastuzumab and a taxane, separately or in combination\",\n    \"Genomic Features\": \"HER2-positive\",\n    \"FDA-approval status\": \"Approved as a single agent for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy + trastuzumab then surgery\",\n    \"Drug Name\": \"Pertuzumab + Trastuzumab + Docetaxel\",\n    \"Prior Treatment or Resistance Status\": \"Not previously treated with anti-HER2 therapy or chemotherapy for metastatic disease\",\n    \"Genomic Features\": \"HER2-positive\",\n    \"FDA-approval status\": \"Approved for treatment of patients with HER2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy + trastuzumab then surgery\",\n    \"Drug Name\": \"Pertuzumab + Trastuzumab + Docetaxel\",\n    \"Prior Treatment or Resistance Status\": \"Previously treated with neoadjuvant chemotherapy and trastuzumab\",\n    \"Genomic Features\": \"HER2-positive\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy + trastuzumab then surgery\",\n    \"Drug Name\": \"Ado-Trastuzumab Emtansine\",\n    \"Prior Treatment or Resistance Status\": \"Previously treated with trastuzumab and a taxane, separately or in combination\",\n    \"Genomic Features\": \"HER2-positive\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy + trastuzumab then surgery\",\n    \"Drug Name\": \"Pertuzumab + Trastuzumab + Docetaxel\",\n    \"Prior Treatment or Resistance Status\": \"Previously treated with neoadjuvant chemotherapy and trastuzumab\",\n    \"Genomic Features\": \"HER2-positive\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy + trastuzumab then surgery\",\n    \"Drug Name\": \"Ado-Trastuzumab Emtansine\",\n    \"Prior Treatment or Resistance Status\": \"Previously treated with trastuzumab and a taxane, separately or in combination\",\n    \"Genomic Features\": \"HER2-positive\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy + trastuzumab then surgery\",\n    \"Drug Name\": \"Pertuzumab + Trastuzumab + Docetaxel\",\n    \"Prior Treatment or Resistance Status\": \"Previously treated with neoadjuvant chemotherapy and trastuzumab\",\n    \"Genomic Features\": \"HER2-positive\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy + trastuzumab then surgery\",\n    \"Drug Name\": \"Ado-Trastuzumab Emtansine\",\n    \"Prior Treatment or Resistance Status\": \"Previously treated with trastuzumab and a taxane, separately or in combination\",\n    \"Genomic Features\": \"HER2-positive\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n  }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced or metastatic, one recommended treatment would be Neratinib + Capecitabine. The U.S. Food and Drug Administration (FDA) approved neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced or metastatic, one recommended treatment would be Neratinib + Capecitabine. The U.S. Food and Drug Administration (FDA) approved neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced or metastatic, one recommended treatment would be Neratinib + Capecitabine. The U.S. Food and Drug Administration (FDA) approved neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced or metastatic, one recommended treatment would be Neratinib + Capecitabine. The U.S. Food and Drug Administration (FDA) approved neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced or metastatic, one recommended treatment would be Neratinib + Capecitabine. The U.S. Food and Drug Administration (FDA) approved neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n         \n    "
        ],
        [
         "5",
         "q5",
         "For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "Yes, the TRK inhibitors Entrectinib and Larotrectinib are approved for use for the treatment of patients with any solid tumor harboring an NTRK1/2/3 fusion. Repotrectinib was also approved after the release of the version of MOAlamanc used in the study.",
         "[{'entrectinib'}, {'larotrectinib'}]",
         "2",
         "0",
         "0",
         "0",
         "{frozenset({'entrectinib'}), frozenset({'larotrectinib'})}",
         "{frozenset({'entrectinib'}), frozenset({'larotrectinib'})}",
         "{frozenset({'entrectinib'}), frozenset({'larotrectinib'})}",
         "{frozenset({'entrectinib'}), frozenset({'larotrectinib'})}",
         "{frozenset({'entrectinib'}), frozenset({'larotrectinib'})}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Solid Tumors\",\n    \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n    \"Drug Name\": \"Entrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Progressed following treatment or have no satisfactory standard therapy\",\n    \"Genomic Features\": \"NTRK gene fusion (NTRK1, NTRK2, or NTRK3)\",\n    \"FDA-approval status\": \"Accelerated approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Solid Tumors\",\n    \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n    \"Drug Name\": \"Larotrectinib\",\n    \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n    \"Genomic Features\": \"NTRK gene fusions (NTRK1, NTRK2, or NTRK3)\",\n    \"FDA-approval status\": \"Approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Solid Tumors with NTRK Gene Fusions\",\n    \"Disease Phase or Condition\": \"Advanced, metastatic, or where surgical resection is likely to result in severe morbidity\",\n    \"Drug Name\": \"Entrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n    \"Genomic Features\": \"NTRK gene fusion (NTRK1, NTRK2, or NTRK3)\",\n    \"FDA-approval status\": \"Accelerated approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Solid Tumors with NTRK Gene Fusions\",\n    \"Disease Phase or Condition\": \"Advanced, metastatic, or where surgical resection is likely to result in severe morbidity\",\n    \"Drug Name\": \"Larotrectinib\",\n    \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n    \"Genomic Features\": \"NTRK gene fusions (NTRK1, NTRK2, or NTRK3) without a known resistance mechanism\",\n    \"FDA-approval status\": \"Approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Solid Tumors with NTRK Gene Fusions\",\n    \"Disease Phase or Condition\": \"Advanced, metastatic, or where surgical resection is likely to result in severe morbidity\",\n    \"Drug Name\": \"Entrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n    \"Genomic Features\": \"NTRK gene fusion (NTRK1, NTRK2, or NTRK3)\",\n    \"FDA-approval status\": \"Accelerated approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Solid Tumors with NTRK Gene Fusions\",\n    \"Disease Phase or Condition\": \"Advanced, metastatic, or where surgical resection is likely to result in severe morbidity\",\n    \"Drug Name\": \"Larotrectinib\",\n    \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n    \"Genomic Features\": \"NTRK gene fusions (NTRK1, NTRK2, or NTRK3) without a known resistance mechanism\",\n    \"FDA-approval status\": \"Approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Solid Tumors with NTRK Gene Fusions\",\n    \"Disease Phase or Condition\": \"Advanced, metastatic, or where surgical resection is likely to result in severe morbidity\",\n    \"Drug Name\": \"Entrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n    \"Genomic Features\": \"NTRK gene fusion (NTRK1, NTRK2, or NTRK3)\",\n    \"FDA-approval status\": \"Accelerated approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Solid Tumors with NTRK Gene Fusions\",\n    \"Disease Phase or Condition\": \"Advanced, metastatic, or where surgical resection is likely to result in severe morbidity\",\n    \"Drug Name\": \"Larotrectinib\",\n    \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n    \"Genomic Features\": \"NTRK gene fusions (NTRK1, NTRK2, or NTRK3) without a known resistance mechanism\",\n    \"FDA-approval status\": \"Approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Solid Tumors with NTRK Gene Fusions\",\n    \"Disease Phase or Condition\": \"Advanced, metastatic, or where surgical resection is likely to result in severe morbidity\",\n    \"Drug Name\": \"Entrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n    \"Genomic Features\": \"NTRK gene fusion (NTRK1, NTRK2, or NTRK3)\",\n    \"FDA-approval status\": \"Accelerated approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Solid Tumors with NTRK Gene Fusions\",\n    \"Disease Phase or Condition\": \"Advanced, metastatic, or where surgical resection is likely to result in severe morbidity\",\n    \"Drug Name\": \"Larotrectinib\",\n    \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n    \"Genomic Features\": \"NTRK gene fusions (NTRK1, NTRK2, or NTRK3) without a known resistance mechanism\",\n    \"FDA-approval status\": \"Approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n  }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted approval for entrectinib for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is locally advanced or metastatic, one recommended treatment would be Repotrectinib. The U.S. Food and Drug Administration (FDA) granted approval to repotrectinib for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Citation: Bristol-Myers Squibb Company. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted approval for entrectinib for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is locally advanced or metastatic, one recommended treatment would be Repotrectinib. The U.S. Food and Drug Administration (FDA) granted approval to repotrectinib for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Citation: Bristol-Myers Squibb Company. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted approval for entrectinib for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is locally advanced or metastatic, one recommended treatment would be Repotrectinib. The U.S. Food and Drug Administration (FDA) granted approval to repotrectinib for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Citation: Bristol-Myers Squibb Company. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted approval for entrectinib for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is locally advanced or metastatic, one recommended treatment would be Repotrectinib. The U.S. Food and Drug Administration (FDA) granted approval to repotrectinib for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Citation: Bristol-Myers Squibb Company. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted approval for entrectinib for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is locally advanced or metastatic, one recommended treatment would be Repotrectinib. The U.S. Food and Drug Administration (FDA) granted approval to repotrectinib for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Citation: Bristol-Myers Squibb Company. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?\n         \n    "
        ],
        [
         "6",
         "q6",
         "For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "Yes, Keytruda (pembrolizumab) is approved by the FDA for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>=10 mutations/megabase (mut/Mb)] solid tumors.",
         "[{'pembrolizumab'}]",
         "1",
         "0",
         "0",
         "0",
         "{frozenset({'pembrolizumab'})}",
         "{frozenset({'pembrolizumab'})}",
         "{frozenset({'pembrolizumab'})}",
         "{frozenset({'pembrolizumab'})}",
         "{frozenset({'pembrolizumab'})}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Solid Tumors\",\n    \"Disease Phase or Condition\": \"Advanced, unresectable or metastatic\",\n    \"Drug Name\": \"Pembrolizumab\",\n    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n    \"Genomic Features\": \"Tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Solid Tumors\",\n    \"Disease Phase or Condition\": \"Advanced, unresectable or metastatic\",\n    \"Drug Name\": \"Pembrolizumab\",\n    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n    \"Genomic Features\": \"Tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Solid Tumors\",\n    \"Disease Phase or Condition\": \"Advanced, unresectable or metastatic\",\n    \"Drug Name\": \"Pembrolizumab\",\n    \"Prior Treatment or Resistance Status\": \"That have progressed following prior treatment and who have no satisfactory alternative treatment options\",\n    \"Genomic Features\": \"Tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Solid Tumors\",\n    \"Disease Phase or Condition\": \"Advanced, unresectable or metastatic\",\n    \"Drug Name\": \"Pembrolizumab\",\n    \"Prior Treatment or Resistance Status\": \"That have progressed following prior treatment and who have no satisfactory alternative treatment options\",\n    \"Genomic Features\": \"Tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Solid Tumors\",\n    \"Disease Phase or Condition\": \"Advanced, unresectable or metastatic\",\n    \"Drug Name\": \"Pembrolizumab\",\n    \"Prior Treatment or Resistance Status\": \"That have progressed following prior treatment and who have no satisfactory alternative treatment options\",\n    \"Genomic Features\": \"Tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n  }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a endometrial cancer patient is MSI-high, and is primary advanced or recurrent, one recommended treatment would be Dostarlimab-gxly. The U.S. Food and Drug Administration (FDA) granted approval to dostarlimab-gxly in combination with carboplatin and paclitaxel, followed by single agent dostarlimab-gxly, for the treatment of adult patients primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite-instability-high. (Citation: GlaxoSmithKline LLC. Jemperli (dostarlimab-gxly) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s006lbl.pdf. Revised July 2023. Accessed September 6, 2023.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced or metastatic, one recommended treatment would be Neratinib + Capecitabine. The U.S. Food and Drug Administration (FDA) approved neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 20 insertion), and is locally advanced or metastatic disease which has progressed on or after platinum-based chemotherapy., one recommended treatment would be Mobocertinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. (Citation: Takeda Pharmaceuticals America, Inc. Exkivity (mobocertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf. Revised September 2021. Accessed September 16th, 2021.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a endometrial cancer patient is MSI-high, and is primary advanced or recurrent, one recommended treatment would be Dostarlimab-gxly. The U.S. Food and Drug Administration (FDA) granted approval to dostarlimab-gxly in combination with carboplatin and paclitaxel, followed by single agent dostarlimab-gxly, for the treatment of adult patients primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite-instability-high. (Citation: GlaxoSmithKline LLC. Jemperli (dostarlimab-gxly) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s006lbl.pdf. Revised July 2023. Accessed September 6, 2023.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced or metastatic, one recommended treatment would be Neratinib + Capecitabine. The U.S. Food and Drug Administration (FDA) approved neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 20 insertion), and is locally advanced or metastatic disease which has progressed on or after platinum-based chemotherapy., one recommended treatment would be Mobocertinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. (Citation: Takeda Pharmaceuticals America, Inc. Exkivity (mobocertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf. Revised September 2021. Accessed September 16th, 2021.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a endometrial cancer patient is MSI-high, and is primary advanced or recurrent, one recommended treatment would be Dostarlimab-gxly. The U.S. Food and Drug Administration (FDA) granted approval to dostarlimab-gxly in combination with carboplatin and paclitaxel, followed by single agent dostarlimab-gxly, for the treatment of adult patients primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite-instability-high. (Citation: GlaxoSmithKline LLC. Jemperli (dostarlimab-gxly) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s006lbl.pdf. Revised July 2023. Accessed September 6, 2023.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced or metastatic, one recommended treatment would be Neratinib + Capecitabine. The U.S. Food and Drug Administration (FDA) approved neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 20 insertion), and is locally advanced or metastatic disease which has progressed on or after platinum-based chemotherapy., one recommended treatment would be Mobocertinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. (Citation: Takeda Pharmaceuticals America, Inc. Exkivity (mobocertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf. Revised September 2021. Accessed September 16th, 2021.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a endometrial cancer patient is MSI-high, and is primary advanced or recurrent, one recommended treatment would be Dostarlimab-gxly. The U.S. Food and Drug Administration (FDA) granted approval to dostarlimab-gxly in combination with carboplatin and paclitaxel, followed by single agent dostarlimab-gxly, for the treatment of adult patients primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite-instability-high. (Citation: GlaxoSmithKline LLC. Jemperli (dostarlimab-gxly) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s006lbl.pdf. Revised July 2023. Accessed September 6, 2023.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced or metastatic, one recommended treatment would be Neratinib + Capecitabine. The U.S. Food and Drug Administration (FDA) approved neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 20 insertion), and is locally advanced or metastatic disease which has progressed on or after platinum-based chemotherapy., one recommended treatment would be Mobocertinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. (Citation: Takeda Pharmaceuticals America, Inc. Exkivity (mobocertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf. Revised September 2021. Accessed September 16th, 2021.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a endometrial cancer patient is MSI-high, and is primary advanced or recurrent, one recommended treatment would be Dostarlimab-gxly. The U.S. Food and Drug Administration (FDA) granted approval to dostarlimab-gxly in combination with carboplatin and paclitaxel, followed by single agent dostarlimab-gxly, for the treatment of adult patients primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite-instability-high. (Citation: GlaxoSmithKline LLC. Jemperli (dostarlimab-gxly) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s006lbl.pdf. Revised July 2023. Accessed September 6, 2023.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced or metastatic, one recommended treatment would be Neratinib + Capecitabine. The U.S. Food and Drug Administration (FDA) approved neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 20 insertion), and is locally advanced or metastatic disease which has progressed on or after platinum-based chemotherapy., one recommended treatment would be Mobocertinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. (Citation: Takeda Pharmaceuticals America, Inc. Exkivity (mobocertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf. Revised September 2021. Accessed September 16th, 2021.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?\n         \n    "
        ],
        [
         "7",
         "q7",
         "What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "While no drugs are approved for use by the US FDA specifically for the treatment of patients with NTRK fusion positive pancreatic adenocarcinoma, a few therapies have received approval for use in any solid tumor that harbors an NTRK fusion. These include: Entrectinib, Larotrectinib. Repotrectinib was also approved after the release of the version of MOAlamanc used in the study.",
         "[{'entrectinib'}, {'larotrectinib'}]",
         "2",
         "0",
         "0",
         "0",
         "{frozenset({'entrectinib'}), frozenset({'larotrectinib'})}",
         "{frozenset({'entrectinib'}), frozenset({'larotrectinib'})}",
         "{frozenset({'entrectinib'}), frozenset({'larotrectinib'})}",
         "{frozenset({'entrectinib'}), frozenset({'larotrectinib'})}",
         "{frozenset({'entrectinib'}), frozenset({'larotrectinib'})}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Pancreatic ductal adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Stage IV\",\n    \"Drug Name\": \"Entrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Has progressed following treatment or has no satisfactory standard therapy\",\n    \"Genomic Features\": \"NTRK gene fusion in NTRK1, NTRK2, or NTRK3\",\n    \"FDA-approval status\": \"Accelerated approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Pancreatic ductal adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Stage IV\",\n    \"Drug Name\": \"Larotrectinib\",\n    \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or has progressed following treatment\",\n    \"Genomic Features\": \"NTRK gene fusions without a known resistance mechanism\",\n    \"FDA-approval status\": \"Approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Pancreatic ductal adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Stage IV\",\n    \"Drug Name\": \"Entrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy\",\n    \"Genomic Features\": \"NTRK gene fusion (NTRK1, NTRK2, or NTRK3)\",\n    \"FDA-approval status\": \"Accelerated approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Pancreatic ductal adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Stage IV\",\n    \"Drug Name\": \"Larotrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment\",\n    \"Genomic Features\": \"NTRK gene fusions without a known resistance mechanism\",\n    \"FDA-approval status\": \"Approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Pancreatic ductal adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Stage IV\",\n    \"Drug Name\": \"Entrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy\",\n    \"Genomic Features\": \"NTRK gene fusion (NTRK1, NTRK2, or NTRK3)\",\n    \"FDA-approval status\": \"Accelerated approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Pancreatic ductal adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Stage IV\",\n    \"Drug Name\": \"Larotrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment\",\n    \"Genomic Features\": \"NTRK gene fusions without a known resistance mechanism\",\n    \"FDA-approval status\": \"Approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Pancreatic ductal adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Stage IV\",\n    \"Drug Name\": \"Entrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Has progressed following treatment or has no satisfactory standard therapy\",\n    \"Genomic Features\": \"NTRK gene fusion in NTRK1, NTRK2, or NTRK3\",\n    \"FDA-approval status\": \"Accelerated approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Pancreatic ductal adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Stage IV\",\n    \"Drug Name\": \"Larotrectinib\",\n    \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or has progressed following treatment\",\n    \"Genomic Features\": \"NTRK gene fusions without a known resistance mechanism\",\n    \"FDA-approval status\": \"Approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Pancreatic ductal adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Stage IV\",\n    \"Drug Name\": \"Entrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Has progressed following treatment or has no satisfactory standard therapy\",\n    \"Genomic Features\": \"NTRK gene fusion in NTRK1, NTRK2, or NTRK3\",\n    \"FDA-approval status\": \"Accelerated approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Pancreatic ductal adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Stage IV\",\n    \"Drug Name\": \"Larotrectinib\",\n    \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or has progressed following treatment\",\n    \"Genomic Features\": \"NTRK gene fusions without a known resistance mechanism\",\n    \"FDA-approval status\": \"Approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n  }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation\n         \n    "
        ],
        [
         "8",
         "q8",
         "What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "There are not currently approved therapies for use from the US FDA for the treatment of patients with FGFR2 mutated bladder cancer.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n         \n    "
        ],
        [
         "9",
         "q9",
         "A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any treatments for use for the treatment of patients with localized or relapsed Ewing sarcoma with STAG2 mutations.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2045C>G or p.A682G), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2045C>G or p.A682G), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2045C>G or p.A682G), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2045C>G or p.A682G), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2045C>G or p.A682G), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n         \n    "
        ],
        [
         "10",
         "q10",
         "A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n         \n    "
        ],
        [
         "11",
         "q11",
         "I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a somatic variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a somatic variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a somatic variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a somatic variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a ovarian cancer patient has a somatic variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n         \n    "
        ],
        [
         "12",
         "q12",
         "My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma",
         "[]",
         "0",
         "0",
         "1",
         "0",
         "{frozenset({'entrectinib'})}",
         "{frozenset({'entrectinib'})}",
         "{frozenset({'entrectinib'})}",
         "{frozenset({'entrectinib'})}",
         "{frozenset({'entrectinib'})}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Neuroblastoma\",\n    \"Disease Phase or Condition\": \"Relapsed/Refractory, Metastatic\",\n    \"Drug Name\": \"Entrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Failed therapy with broad chemotherapy, radiation, and an ALK inhibitor\",\n    \"Genomic Features\": \"ALK rearrangement\",\n    \"FDA-approval status\": \"Accelerated approval for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy.\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Neuroblastoma\",\n    \"Disease Phase or Condition\": \"Relapsed/Refractory, Metastatic\",\n    \"Drug Name\": \"Entrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Failed therapy with broad chemotherapy, radiation, and an ALK inhibitor\",\n    \"Genomic Features\": \"ALK mutation\",\n    \"FDA-approval status\": \"Accelerated approval for solid tumors with NTRK gene fusions, including ALK rearrangements, that have progressed following treatment or have no satisfactory alternative treatments\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Neuroblastoma\",\n    \"Disease Phase or Condition\": \"Relapsed/Refractory, Metastatic\",\n    \"Drug Name\": \"Entrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Failed therapy with broad chemotherapy, radiation, and an ALK inhibitor\",\n    \"Genomic Features\": \"ALK mutation\",\n    \"FDA-approval status\": \"Accelerated approval for solid tumors with NTRK gene fusions, including ALK rearrangements, that have progressed following treatment or have no satisfactory alternative treatments\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Neuroblastoma\",\n    \"Disease Phase or Condition\": \"Relapsed/Refractory, Metastatic\",\n    \"Drug Name\": \"Entrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Failed therapy with broad chemotherapy, radiation, and an ALK inhibitor\",\n    \"Genomic Features\": \"ALK mutation\",\n    \"FDA-approval status\": \"Accelerated approval for solid tumors with NTRK gene fusions, including ALK rearrangements, that have progressed following treatment or have no satisfactory alternative treatments\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Neuroblastoma\",\n    \"Disease Phase or Condition\": \"Relapsed/Refractory, Metastatic\",\n    \"Drug Name\": \"Entrectinib\",\n    \"Prior Treatment or Resistance Status\": \"Failed therapy with broad chemotherapy, radiation, and an ALK inhibitor\",\n    \"Genomic Features\": \"ALK mutation\",\n    \"FDA-approval status\": \"Accelerated approval for solid tumors with NTRK gene fusions, including ALK rearrangements, that have progressed following treatment or have no satisfactory alternative treatments\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n  }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n         \n    "
        ],
        [
         "13",
         "q13",
         "For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with osteosarcoma",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n         \n    "
        ],
        [
         "14",
         "q14",
         "Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?",
         "True",
         "True",
         "given disease and biomarker, return drugs; not included in the version of MOAlamanc used in the study",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with KMT2A translocation positive AML. However, Revumenib was approved on November, 2024, which is not included in the version of MOAlamanc used in the study.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>A or p.R132S), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>G or p.R132G), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>T or p.R132L), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.515G>A or p.R172K), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.516G>T or p.R172S), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.419G>A or p.R140Q), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>A or p.R132S), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>G or p.R132G), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>T or p.R132L), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.515G>A or p.R172K), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.516G>T or p.R172S), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.419G>A or p.R140Q), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>A or p.R132S), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>G or p.R132G), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>T or p.R132L), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.515G>A or p.R172K), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.516G>T or p.R172S), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.419G>A or p.R140Q), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>A or p.R132S), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>G or p.R132G), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>T or p.R132L), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.515G>A or p.R172K), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.516G>T or p.R172S), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.419G>A or p.R140Q), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>A or p.R132S), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>G or p.R132G), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>T or p.R132L), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.515G>A or p.R172K), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.516G>T or p.R172S), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.419G>A or p.R140Q), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n         \n    "
        ],
        [
         "15",
         "q15",
         "For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with medulloblastoma, does not have access to clinical trial information.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "{frozenset({'sonidegib'})}",
         "set()",
         "set()",
         "set()",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Medulloblastoma\",\n    \"Disease Phase or Condition\": \"SHH subtype\",\n    \"Drug Name\": \"Sonidegib\",\n    \"Prior Treatment or Resistance Status\": \"No prior treatment specified\",\n    \"Genomic Features\": \"Germline PTCH1 mutation\",\n    \"FDA-approval status\": \"Accelerated approval\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208872s000lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a subependymal giant cell astrocytoma patient has a somatic variant in gene TSC1, one recommended treatment would be Everolimus. Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection (Citation: Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a subependymal giant cell astrocytoma patient has a somatic variant in gene TSC1, one recommended treatment would be Everolimus. Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection (Citation: Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a subependymal giant cell astrocytoma patient has a somatic variant in gene TSC1, one recommended treatment would be Everolimus. Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection (Citation: Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a subependymal giant cell astrocytoma patient has a somatic variant in gene TSC1, one recommended treatment would be Everolimus. Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection (Citation: Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a subependymal giant cell astrocytoma patient has a somatic variant in gene TSC1, one recommended treatment would be Everolimus. Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection (Citation: Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n         \n    "
        ],
        [
         "16",
         "q16",
         "For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with hepatoblastoma. However, there is clinical evidence that CTNNB1 is associated with favorable prognosis in patients with medulloblastoma.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a somatic variant in gene IDH1, and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a cholangiocarcinoma patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a somatic variant in gene IDH1, and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a cholangiocarcinoma patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a somatic variant in gene IDH1, and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a cholangiocarcinoma patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a somatic variant in gene IDH1, and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a cholangiocarcinoma patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a somatic variant in gene IDH1, and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a cholangiocarcinoma patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n         \n    "
        ],
        [
         "17",
         "q17",
         "I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?",
         "True",
         "True",
         "given disease and biomarker, return drugs; HER2-related",
         "True",
         "Two therapeutic hypotheses to consider for this patient are either PARP or PI3K/Akt/mTOR inhibition, though all treatment options are indicated for patients that have HER2-negative breast cancer. For first line treatment, talazoparib is approved for use and indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. For second line treatments, options will vary depending on the type of first line treatment. Capivasertib in combination with fulvestrant is approved for use for the treatment of adult patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. Olaparib is also approved for use for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative (i) metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting; and (ii) high risk early breast cancer who have been treated with chemotherapy in the neoadjuvant or adjuvant setting.",
         "[{'talazoparib'}, {'capivasertib', 'fulvestrant'}, {'olaparib'}]",
         "2",
         "1",
         "0",
         "0",
         "{frozenset({'olaparib'}), frozenset({'fulvestrant', 'capivasertib'})}",
         "{frozenset({'olaparib'}), frozenset({'fulvestrant', 'capivasertib'})}",
         "{frozenset({'olaparib'}), frozenset({'fulvestrant', 'capivasertib'})}",
         "{frozenset({'olaparib'}), frozenset({'fulvestrant', 'capivasertib'})}",
         "{frozenset({'olaparib'}), frozenset({'fulvestrant', 'capivasertib'})}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic HR+ Breast Cancer\",\n    \"Disease Phase or Condition\": \"De novo metastatic\",\n    \"Drug Name\": \"Capivasertib + Fulvestrant\",\n    \"Prior Treatment or Resistance Status\": \"First-line\",\n    \"Genomic Features\": \"Somatic AKT mutation, Germline BRCA2 mutation\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Metastatic HR+ Breast Cancer\",\n    \"Disease Phase or Condition\": \"De novo metastatic\",\n    \"Drug Name\": \"Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"Second-line (following progression on Capivasertib + Fulvestrant)\",\n    \"Genomic Features\": \"Germline BRCA2 mutation\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic HR+ Breast Cancer\",\n    \"Disease Phase or Condition\": \"De novo metastatic\",\n    \"Drug Name\": \"Capivasertib + Fulvestrant\",\n    \"Prior Treatment or Resistance Status\": \"First-line\",\n    \"Genomic Features\": \"Somatic AKT mutation, Germline BRCA2 mutation\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Metastatic HR+ Breast Cancer\",\n    \"Disease Phase or Condition\": \"De novo metastatic\",\n    \"Drug Name\": \"Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"Second-line (following progression on Capivasertib + Fulvestrant)\",\n    \"Genomic Features\": \"Germline BRCA2 mutation\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic HR+ Breast Cancer\",\n    \"Disease Phase or Condition\": \"De novo metastatic\",\n    \"Drug Name\": \"Capivasertib + Fulvestrant\",\n    \"Prior Treatment or Resistance Status\": \"First-line\",\n    \"Genomic Features\": \"Somatic AKT mutation, Germline BRCA2 mutation\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Metastatic HR+ Breast Cancer\",\n    \"Disease Phase or Condition\": \"De novo metastatic\",\n    \"Drug Name\": \"Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"Second-line (following progression on Capivasertib + Fulvestrant)\",\n    \"Genomic Features\": \"Germline BRCA2 mutation\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic HR+ Breast Cancer\",\n    \"Disease Phase or Condition\": \"De novo metastatic\",\n    \"Drug Name\": \"Capivasertib + Fulvestrant\",\n    \"Prior Treatment or Resistance Status\": \"First-line\",\n    \"Genomic Features\": \"Somatic AKT mutation, Germline BRCA2 mutation\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Metastatic HR+ Breast Cancer\",\n    \"Disease Phase or Condition\": \"De novo metastatic\",\n    \"Drug Name\": \"Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"Second-line (following progression on Capivasertib + Fulvestrant)\",\n    \"Genomic Features\": \"Germline BRCA2 mutation\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic HR+ Breast Cancer\",\n    \"Disease Phase or Condition\": \"De novo metastatic\",\n    \"Drug Name\": \"Capivasertib + Fulvestrant\",\n    \"Prior Treatment or Resistance Status\": \"First-line\",\n    \"Genomic Features\": \"Somatic AKT mutation, Germline BRCA2 mutation\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Metastatic HR+ Breast Cancer\",\n    \"Disease Phase or Condition\": \"De novo metastatic\",\n    \"Drug Name\": \"Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"Second-line (following progression on Capivasertib + Fulvestrant)\",\n    \"Genomic Features\": \"Germline BRCA2 mutation\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a somatic variant in gene PIK3CA, and is advanced or metastatic, one recommended treatment would be Alpelisib. Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. (Citation: Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a somatic variant in gene AKT1, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (frameshift), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (splice site), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PIK3CA, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (nonsense), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene PTEN, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a somatic variant in gene PIK3CA, and is advanced or metastatic, one recommended treatment would be Alpelisib. Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. (Citation: Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a somatic variant in gene AKT1, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (frameshift), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (splice site), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PIK3CA, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (nonsense), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene PTEN, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a somatic variant in gene PIK3CA, and is advanced or metastatic, one recommended treatment would be Alpelisib. Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. (Citation: Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a somatic variant in gene AKT1, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (frameshift), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (splice site), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PIK3CA, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (nonsense), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene PTEN, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a somatic variant in gene PIK3CA, and is advanced or metastatic, one recommended treatment would be Alpelisib. Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. (Citation: Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a somatic variant in gene AKT1, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (frameshift), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (splice site), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PIK3CA, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (nonsense), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene PTEN, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a somatic variant in gene PIK3CA, and is advanced or metastatic, one recommended treatment would be Alpelisib. Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. (Citation: Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a somatic variant in gene AKT1, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (frameshift), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (splice site), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PIK3CA, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (nonsense), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene PTEN, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n         \n    "
        ],
        [
         "18",
         "q18",
         "I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?",
         "True",
         "True",
         "given disease and biomarker, return drugs; HER2-related",
         "True",
         "While this version of MOAlmanac does not directly curate HER2+ status as a biomarker, a number of FDA approvals and companion diagnostics include ERBB2 amplifications for approvals based on HER2+. For FDA approvals for patients with breast cancer: Ado-Trastuzumab Emtansine; Capecitabine + Trastuzumab + Tucatinib; Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab; Lapatinib; Margetuximab-cmkb + Chemotherapy; Neratinib; Neratinib + Capecitabine; Pertuzumab + Trastuzumab; Trastuzumab; Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab",
         "[{'ado-trastuzumab emtansine'}, {'trastuzumab', 'tucatinib', 'capecitabine'}, {'trastuzumab', 'hyaluronidase-zzxf', 'pertuzumab', 'chemotherapy'}, {'lapatinib'}, {'chemotherapy', 'margetuximab-cmkb'}, {'neratinib'}, {'capecitabine', 'neratinib'}, {'trastuzumab', 'pertuzumab'}, {'trastuzumab'}, {'trastuzumab', 'pertuzumab', 'hyaluronidase-zzxf', 'docetaxel'}, {'trastuzumab', 'pertuzumab', 'docetaxel'}]",
         "1",
         "10",
         "0",
         "0",
         "{frozenset({'docetaxel', 'trastuzumab', 'pertuzumab'})}",
         "{frozenset({'docetaxel', 'trastuzumab', 'pertuzumab'})}",
         "{frozenset({'docetaxel', 'trastuzumab', 'pertuzumab'})}",
         "{frozenset({'docetaxel', 'trastuzumab', 'pertuzumab'})}",
         "{frozenset({'docetaxel', 'trastuzumab', 'pertuzumab'})}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Early stage, high risk of recurrence\",\n    \"Drug Name\": \"Pertuzumab + Trastuzumab + Docetaxel\",\n    \"Prior Treatment or Resistance Status\": \"Previously received neoadjuvant TCHP\",\n    \"Genomic Features\": \"HER2-positive\",\n    \"FDA-approval status\": \"Approved for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease, and in combination with trastuzumab and docetaxel as neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer.\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n  },\n  \"Clinical Trials\": [\n    {\n      \"Trial Name\": \"PHEREXA\",\n      \"Trial Description\": \"A phase III trial evaluating pertuzumab, trastuzumab, and docetaxel as neoadjuvant treatment in patients with HER2-positive early breast cancer.\",\n      \"Link\": \"https://clinicaltrials.gov/ct2/show/NCT01054312\"\n    },\n    {\n      \"Trial Name\": \"APHINITY\",\n      \"Trial Description\": \"A phase III trial evaluating pertuzumab in combination with trastuzumab and docetaxel as neoadjuvant treatment in patients with HER2-positive early breast cancer.\",\n      \"Link\": \"https://clinicaltrials.gov/ct2/show/NCT01358877\"\n    }\n  ]\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Early stage, high risk of recurrence\",\n    \"Drug Name\": \"Pertuzumab + Trastuzumab + Docetaxel\",\n    \"Prior Treatment or Resistance Status\": \"Received neoadjuvant TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab)\",\n    \"Genomic Features\": \"HER2-positive\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\"\n  },\n  \"Clinical Trials\": [\n    {\n      \"Trial Name\": \"Adjuvant Pertuzumab and Trastuzumab in Early Stage HER2-Positive Breast Cancer (APHINITY)\",\n      \"Trial ID\": \"NCT01358877\",\n      \"Description\": \"A phase 3 trial comparing pertuzumab plus trastuzumab versus trastuzumab alone as adjuvant therapy in patients with early-stage HER2-positive breast cancer.\"\n    },\n    {\n      \"Trial Name\": \"KATHERINE Trial: Adjuvant Tucatinib, Trastuzumab, and Capecitabine in HER2-Positive Early Stage Breast Cancer\",\n      \"Trial ID\": \"NCT03776168\",\n      \"Description\": \"A phase 3 trial evaluating the efficacy and safety of adjuvant tucatinib in combination with trastuzumab and capecitabine in patients with HER2-positive early-stage breast cancer at high risk of recurrence.\"\n    }\n  ]\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Early stage, high risk of recurrence\",\n    \"Drug Name\": \"Pertuzumab + Trastuzumab + Docetaxel\",\n    \"Prior Treatment or Resistance Status\": \"Previously received neoadjuvant TCHP\",\n    \"Genomic Features\": \"HER2-positive\",\n    \"FDA-approval status\": \"Approved for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease, and in combination with trastuzumab and docetaxel as neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer.\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n  },\n  \"Clinical Trials\": [\n    {\n      \"Trial Name\": \"PHEREXA\",\n      \"Trial Description\": \"A phase III trial evaluating pertuzumab, trastuzumab, and docetaxel as neoadjuvant treatment in patients with HER2-positive early breast cancer.\",\n      \"Link\": \"https://clinicaltrials.gov/ct2/show/NCT01054312\"\n    },\n    {\n      \"Trial Name\": \"APHINITY\",\n      \"Trial Description\": \"A phase III trial evaluating pertuzumab in combination with trastuzumab and docetaxel as neoadjuvant treatment in patients with HER2-positive early breast cancer.\",\n      \"Link\": \"https://clinicaltrials.gov/ct2/show/NCT01358877\"\n    }\n  ]\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Early stage, high risk of recurrence\",\n    \"Drug Name\": \"Pertuzumab + Trastuzumab + Docetaxel\",\n    \"Prior Treatment or Resistance Status\": \"Received neoadjuvant TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab)\",\n    \"Genomic Features\": \"HER2-positive\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\"\n  },\n  \"Clinical Trials\": [\n    {\n      \"Trial Name\": \"Adjuvant Pertuzumab and Trastuzumab in Early Stage HER2-Positive Breast Cancer (APHINITY)\",\n      \"Trial ID\": \"NCT01358877\",\n      \"Description\": \"A phase 3 trial comparing pertuzumab plus trastuzumab versus trastuzumab alone as adjuvant therapy in patients with early-stage HER2-positive breast cancer.\"\n    },\n    {\n      \"Trial Name\": \"KATHERINE Trial: Adjuvant Tucatinib, Trastuzumab, and Capecitabine in HER2-Positive Early Stage Breast Cancer\",\n      \"Trial ID\": \"NCT03776168\",\n      \"Description\": \"A phase 3 trial evaluating the efficacy and safety of adjuvant tucatinib in combination with trastuzumab and capecitabine in patients with HER2-positive early-stage breast cancer at high risk of recurrence.\"\n    }\n  ]\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Early stage, high risk of recurrence\",\n    \"Drug Name\": \"Pertuzumab + Trastuzumab + Docetaxel\",\n    \"Prior Treatment or Resistance Status\": \"Previously received neoadjuvant TCHP\",\n    \"Genomic Features\": \"HER2-positive\",\n    \"FDA-approval status\": \"Approved for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease, and in combination with trastuzumab and docetaxel as neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer.\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n  },\n  \"Clinical Trials\": [\n    {\n      \"Trial Name\": \"PHEREXA\",\n      \"Trial Description\": \"A phase III trial evaluating pertuzumab, trastuzumab, and docetaxel as neoadjuvant treatment in patients with HER2-positive early breast cancer.\",\n      \"Link\": \"https://clinicaltrials.gov/ct2/show/NCT01054312\"\n    },\n    {\n      \"Trial Name\": \"APHINITY\",\n      \"Trial Description\": \"A phase III trial evaluating pertuzumab in combination with trastuzumab and docetaxel as neoadjuvant treatment in patients with HER2-positive early breast cancer.\",\n      \"Link\": \"https://clinicaltrials.gov/ct2/show/NCT01358877\"\n    }\n  ]\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene PTEN, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (splice site), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene PTEN, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (splice site), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene PTEN, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (splice site), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene PTEN, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (splice site), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene PTEN, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (splice site), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n         \n    "
        ],
        [
         "19",
         "q19",
         "I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?",
         "True",
         "True",
         "given disease and biomarker, return drugs; not included in the version of MOAlamanc used in the study",
         "True",
         "Either T-DXd or SG could be used; we generally use SG at this point given a large phase III trial (ASCENT) with PFS and OS benefit. Destiny-BREAST04 had a smaller cohort of TNBC. Both T-DXd and SG are FDA approved for MBC after 1+ prior lines of chemotherapy; SG is approved for HER2 null, while T-DXd is approved for HER2-low or -ultralow. T-DXd is associated with higher rates of interstitial lung disease, and cardiac function must be monitored given anti-HER2 activity. SG has more dense alopecia and higher rates of neutropenia.",
         "[{'sacituzumab govitecan'}, {'trastuzumab deruxtecan'}]",
         "1",
         "1",
         "0",
         "0",
         "{frozenset({'sacituzumab govitecan'})}",
         "{frozenset({'sacituzumab govitecan'})}",
         "{frozenset({'sacituzumab govitecan'})}",
         "{frozenset({'sacituzumab govitecan'})}",
         "{frozenset({'sacituzumab govitecan'})}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Metastatic, HR-negative, HER2-low, PD-L1-negative\",\n    \"Drug Name\": \"Sacituzumab govitecan\",\n    \"Prior Treatment or Resistance Status\": \"Second line\",\n    \"Genomic Features\": \"No germline BRCA mutation\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213326s000lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic HR-negative, HER2-low, PD-L1-negative breast cancer\",\n    \"Disease Phase or Condition\": \"Second line\",\n    \"Drug Name\": \"Sacituzumab govitecan\",\n    \"Prior Treatment or Resistance Status\": \"Second line\",\n    \"Genomic Features\": \"HER2-low\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213410s000lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Metastatic, HR-negative, HER2-low, PD-L1-negative\",\n    \"Drug Name\": \"Sacituzumab govitecan\",\n    \"Prior Treatment or Resistance Status\": \"Second line\",\n    \"Genomic Features\": \"No germline BRCA mutation\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213326s000lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Cancer\",\n    \"Disease Phase or Condition\": \"Metastatic, HR-negative, HER2-low, PD-L1-negative\",\n    \"Drug Name\": \"Sacituzumab govitecan\",\n    \"Prior Treatment or Resistance Status\": \"Second line\",\n    \"Genomic Features\": \"No germline BRCA mutation\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213326s000lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic breast cancer\",\n    \"Disease Phase or Condition\": \"Second line\",\n    \"Drug Name\": \"Sacituzumab govitecan\",\n    \"Prior Treatment or Resistance Status\": \"Second line\",\n    \"Genomic Features\": \"HR-negative, HER2-low, PD-L1-negative\",\n    \"FDA-approval status\": \"Approved\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213412s000lbl.pdf\"\n  }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n         \n    "
        ],
        [
         "20",
         "q20",
         "If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "The US FDA has approved Erdafitnib for use for the treatment of patients with locally advanced or metastatic  urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy.",
         "[{'erdafitinib'}]",
         "1",
         "0",
         "0",
         "0",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"urothelial carcinoma (bladder cancer)\",\n    \"Disease Phase or Condition\": \"locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy\",\n    \"Drug Name\": \"Erdafitinib\",\n    \"Prior Treatment or Resistance Status\": \"has progressed during or following at least one line of prior platinum containing chemotherapy\",\n    \"Genomic Features\": \"somatic variant in gene FGFR3 (c.1180G>T or p.G370C, c.1118A>G or p.Y373C, c.746C>G or p.S249C, c.742C>T or p.R248C) or rearrangement in gene FGFR3\",\n    \"FDA-approval status\": \"approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"urothelial carcinoma (bladder cancer)\",\n    \"Disease Phase or Condition\": \"locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy\",\n    \"Drug Name\": \"Erdafitinib\",\n    \"Prior Treatment or Resistance Status\": \"has progressed during or following at least one line of prior platinum containing chemotherapy\",\n    \"Genomic Features\": \"somatic variant in gene FGFR3 (c.1180G>T or p.G370C, c.1118A>G or p.Y373C, c.746C>G or p.S249C, c.742C>T or p.R248C) or rearrangement in gene FGFR3\",\n    \"FDA-approval status\": \"approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"urothelial carcinoma (bladder cancer)\",\n    \"Disease Phase or Condition\": \"locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy\",\n    \"Drug Name\": \"Erdafitinib\",\n    \"Prior Treatment or Resistance Status\": \"has progressed during or following at least one line of systemic therapy\",\n    \"Genomic Features\": \"somatic variant in gene FGFR3 (c.1180G>T or p.G370C, c.1118A>G or p.Y373C, c.746C>G or p.S249C, c.742C>T or p.R248C) or rearrangement in gene FGFR3\",\n    \"FDA-approval status\": \"approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with susceptible FGFR3 genetic alterations\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"urothelial carcinoma (bladder cancer)\",\n    \"Disease Phase or Condition\": \"locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy\",\n    \"Drug Name\": \"Erdafitinib\",\n    \"Prior Treatment or Resistance Status\": \"has progressed during or following at least one line of systemic therapy\",\n    \"Genomic Features\": \"somatic variant in gene FGFR3 (c.1180G>T or p.G370C, c.1118A>G or p.Y373C, c.746C>G or p.S249C, c.742C>T or p.R248C) or rearrangement in gene FGFR3\",\n    \"FDA-approval status\": \"approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with susceptible FGFR3 genetic alterations\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n  }\n}",
         "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"urothelial carcinoma (bladder cancer)\",\n    \"Disease Phase or Condition\": \"locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy\",\n    \"Drug Name\": \"Erdafitinib\",\n    \"Prior Treatment or Resistance Status\": \"has progressed during or following at least one line of prior platinum containing chemotherapy\",\n    \"Genomic Features\": \"somatic variant in gene FGFR3 (c.1180G>T or p.G370C, c.1118A>G or p.Y373C, c.746C>G or p.S249C, c.742C>T or p.R248C) or rearrangement in gene FGFR3\",\n    \"FDA-approval status\": \"approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n  }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?\n         \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n        If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n        {\n            \"Status\": \"no_match\",\n            \"Message\": \"No drugs are FDA-approved for the provided context\"\n        }\n        \n        If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n        {\n            \"Status\": \"success\",\n            \"Treatment 1\": {\n                \"Disease Name\": ,\n                \"Disease Phase or Condition\": ,\n                \"Drug Name\": ,\n                \"Prior Treatment or Resistance Status\": ,\n                \"Genomic Features\": \n                \"FDA-approval status\":\n                \"Link to FDA-approved Label\":\n                }\n        }\n        Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?\n         \n    "
        ]
       ],
       "shape": {
        "columns": 27,
        "rows": 21
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question_index</th>\n",
       "      <th>prompt</th>\n",
       "      <th>Asking_therapy</th>\n",
       "      <th>Given_biomarker</th>\n",
       "      <th>Question_category</th>\n",
       "      <th>Is_there_an_approval</th>\n",
       "      <th>Groundtruth_answers</th>\n",
       "      <th>Groundtruth_therapies</th>\n",
       "      <th>matching_cnt</th>\n",
       "      <th>missing_cnt</th>\n",
       "      <th>...</th>\n",
       "      <th>RAGLLM_full_output_0</th>\n",
       "      <th>RAGLLM_full_output_1</th>\n",
       "      <th>RAGLLM_full_output_2</th>\n",
       "      <th>RAGLLM_full_output_3</th>\n",
       "      <th>RAGLLM_full_output_4</th>\n",
       "      <th>RAGLLM_input_prompt_0</th>\n",
       "      <th>RAGLLM_input_prompt_1</th>\n",
       "      <th>RAGLLM_input_prompt_2</th>\n",
       "      <th>RAGLLM_input_prompt_3</th>\n",
       "      <th>RAGLLM_input_prompt_4</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>q0</td>\n",
       "      <td>What is the first-line treatment of metastatic...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>erdafitinib</td>\n",
       "      <td>[{'erdafitinib'}]</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>q1</td>\n",
       "      <td>Are PARP inhibitors used for patients with lei...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>PARP inhibitors are not yet approved for the t...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>q2</td>\n",
       "      <td>Are ALK inhibitors approved for use in TFCP2 f...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>No, no ALK inhibitors are currently approved f...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>q3</td>\n",
       "      <td>For a patient with cancer metastatic prostate ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>The following therapy and combination therapie...</td>\n",
       "      <td>[{'olaparib'}, {'prednisone', 'olaparib', 'abi...</td>\n",
       "      <td>3</td>\n",
       "      <td>2</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>q4</td>\n",
       "      <td>For a patient with HER2+ breast cancer after n...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; HER...</td>\n",
       "      <td>True</td>\n",
       "      <td>TDM-1 (ado-trastuzumab emtansine (Kadcyla))</td>\n",
       "      <td>[{'ado-trastuzumab emtansine'}]</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>q5</td>\n",
       "      <td>For patients with advanced cancer and with NTR...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes, the TRK inhibitors Entrectinib and Larotr...</td>\n",
       "      <td>[{'entrectinib'}, {'larotrectinib'}]</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>q6</td>\n",
       "      <td>For patients with advanced cancer and with hig...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes, Keytruda (pembrolizumab) is approved by t...</td>\n",
       "      <td>[{'pembrolizumab'}]</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>q7</td>\n",
       "      <td>What FDA-approved therapies exist for a Stage ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>While no drugs are approved for use by the US ...</td>\n",
       "      <td>[{'entrectinib'}, {'larotrectinib'}]</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>q8</td>\n",
       "      <td>What are available FDA-approved targeted thera...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>There are not currently approved therapies for...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>q9</td>\n",
       "      <td>A patient with localized Ewing sarcoma has a S...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any treatments...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>q10</td>\n",
       "      <td>A patient with relapsed high-risk neuroblastom...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>q11</td>\n",
       "      <td>I have a 3 year old patient with Neuroblastoma...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>q12</td>\n",
       "      <td>My 20 year old patient with ALK mutated Neurob...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>q13</td>\n",
       "      <td>For a 17-year-old osteosarcoma patient with 50...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>q14</td>\n",
       "      <td>Is there an optimal drug combination to minimi...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; not...</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>q15</td>\n",
       "      <td>For a 4 year old patient with medulloblastoma,...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>q16</td>\n",
       "      <td>For toddler with unresectable hepatoblastoma a...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>q17</td>\n",
       "      <td>I have a patient with de novo metastatic HR+ b...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; HER...</td>\n",
       "      <td>True</td>\n",
       "      <td>Two therapeutic hypotheses to consider for thi...</td>\n",
       "      <td>[{'talazoparib'}, {'capivasertib', 'fulvestran...</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>q18</td>\n",
       "      <td>I have a patient with an initial diagnosis of ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; HER...</td>\n",
       "      <td>True</td>\n",
       "      <td>While this version of MOAlmanac does not direc...</td>\n",
       "      <td>[{'ado-trastuzumab emtansine'}, {'trastuzumab'...</td>\n",
       "      <td>1</td>\n",
       "      <td>10</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>q19</td>\n",
       "      <td>I have a patient with metastatic HR-negative, ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; not...</td>\n",
       "      <td>True</td>\n",
       "      <td>Either T-DXd or SG could be used; we generally...</td>\n",
       "      <td>[{'sacituzumab govitecan'}, {'trastuzumab deru...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>q20</td>\n",
       "      <td>If a bladder cancer patient has FGFR3 mutation...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>The US FDA has approved Erdafitnib for use for...</td>\n",
       "      <td>[{'erdafitinib'}]</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>21 rows × 27 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   Question_index                                             prompt  \\\n",
       "0              q0  What is the first-line treatment of metastatic...   \n",
       "1              q1  Are PARP inhibitors used for patients with lei...   \n",
       "2              q2  Are ALK inhibitors approved for use in TFCP2 f...   \n",
       "3              q3  For a patient with cancer metastatic prostate ...   \n",
       "4              q4  For a patient with HER2+ breast cancer after n...   \n",
       "5              q5  For patients with advanced cancer and with NTR...   \n",
       "6              q6  For patients with advanced cancer and with hig...   \n",
       "7              q7  What FDA-approved therapies exist for a Stage ...   \n",
       "8              q8  What are available FDA-approved targeted thera...   \n",
       "9              q9  A patient with localized Ewing sarcoma has a S...   \n",
       "10            q10  A patient with relapsed high-risk neuroblastom...   \n",
       "11            q11  I have a 3 year old patient with Neuroblastoma...   \n",
       "12            q12  My 20 year old patient with ALK mutated Neurob...   \n",
       "13            q13  For a 17-year-old osteosarcoma patient with 50...   \n",
       "14            q14  Is there an optimal drug combination to minimi...   \n",
       "15            q15  For a 4 year old patient with medulloblastoma,...   \n",
       "16            q16  For toddler with unresectable hepatoblastoma a...   \n",
       "17            q17  I have a patient with de novo metastatic HR+ b...   \n",
       "18            q18  I have a patient with an initial diagnosis of ...   \n",
       "19            q19  I have a patient with metastatic HR-negative, ...   \n",
       "20            q20  If a bladder cancer patient has FGFR3 mutation...   \n",
       "\n",
       "    Asking_therapy  Given_biomarker  \\\n",
       "0             True             True   \n",
       "1             True             True   \n",
       "2             True             True   \n",
       "3             True             True   \n",
       "4             True             True   \n",
       "5             True             True   \n",
       "6             True             True   \n",
       "7             True             True   \n",
       "8             True             True   \n",
       "9             True             True   \n",
       "10            True             True   \n",
       "11            True             True   \n",
       "12            True             True   \n",
       "13            True             True   \n",
       "14            True             True   \n",
       "15            True             True   \n",
       "16            True             True   \n",
       "17            True             True   \n",
       "18            True             True   \n",
       "19            True             True   \n",
       "20            True             True   \n",
       "\n",
       "                                    Question_category  Is_there_an_approval  \\\n",
       "0           given disease and biomarker, return drugs                  True   \n",
       "1           given disease and biomarker, return drugs                 False   \n",
       "2           given disease and biomarker, return drugs                 False   \n",
       "3           given disease and biomarker, return drugs                  True   \n",
       "4   given disease and biomarker, return drugs; HER...                  True   \n",
       "5           given disease and biomarker, return drugs                  True   \n",
       "6           given disease and biomarker, return drugs                  True   \n",
       "7           given disease and biomarker, return drugs                  True   \n",
       "8           given disease and biomarker, return drugs                 False   \n",
       "9           given disease and biomarker, return drugs                 False   \n",
       "10          given disease and biomarker, return drugs                 False   \n",
       "11          given disease and biomarker, return drugs                 False   \n",
       "12          given disease and biomarker, return drugs                 False   \n",
       "13          given disease and biomarker, return drugs                 False   \n",
       "14  given disease and biomarker, return drugs; not...                 False   \n",
       "15          given disease and biomarker, return drugs                 False   \n",
       "16          given disease and biomarker, return drugs                 False   \n",
       "17  given disease and biomarker, return drugs; HER...                  True   \n",
       "18  given disease and biomarker, return drugs; HER...                  True   \n",
       "19  given disease and biomarker, return drugs; not...                  True   \n",
       "20          given disease and biomarker, return drugs                  True   \n",
       "\n",
       "                                  Groundtruth_answers  \\\n",
       "0                                         erdafitinib   \n",
       "1   PARP inhibitors are not yet approved for the t...   \n",
       "2   No, no ALK inhibitors are currently approved f...   \n",
       "3   The following therapy and combination therapie...   \n",
       "4         TDM-1 (ado-trastuzumab emtansine (Kadcyla))   \n",
       "5   Yes, the TRK inhibitors Entrectinib and Larotr...   \n",
       "6   Yes, Keytruda (pembrolizumab) is approved by t...   \n",
       "7   While no drugs are approved for use by the US ...   \n",
       "8   There are not currently approved therapies for...   \n",
       "9   The US FDA has not yet approved any treatments...   \n",
       "10  The US FDA has not yet approved any biomarker-...   \n",
       "11  The US FDA has not yet approved any biomarker-...   \n",
       "12  The US FDA has not yet approved any biomarker-...   \n",
       "13  The US FDA has not yet approved any biomarker-...   \n",
       "14  The US FDA has not yet approved any biomarker-...   \n",
       "15  The US FDA has not yet approved any biomarker-...   \n",
       "16  The US FDA has not yet approved any biomarker-...   \n",
       "17  Two therapeutic hypotheses to consider for thi...   \n",
       "18  While this version of MOAlmanac does not direc...   \n",
       "19  Either T-DXd or SG could be used; we generally...   \n",
       "20  The US FDA has approved Erdafitnib for use for...   \n",
       "\n",
       "                                Groundtruth_therapies  matching_cnt  \\\n",
       "0                                   [{'erdafitinib'}]             1   \n",
       "1                                                  []             0   \n",
       "2                                                  []             0   \n",
       "3   [{'olaparib'}, {'prednisone', 'olaparib', 'abi...             3   \n",
       "4                     [{'ado-trastuzumab emtansine'}]             1   \n",
       "5                [{'entrectinib'}, {'larotrectinib'}]             2   \n",
       "6                                 [{'pembrolizumab'}]             1   \n",
       "7                [{'entrectinib'}, {'larotrectinib'}]             2   \n",
       "8                                                  []             0   \n",
       "9                                                  []             0   \n",
       "10                                                 []             0   \n",
       "11                                                 []             0   \n",
       "12                                                 []             0   \n",
       "13                                                 []             0   \n",
       "14                                                 []             0   \n",
       "15                                                 []             0   \n",
       "16                                                 []             0   \n",
       "17  [{'talazoparib'}, {'capivasertib', 'fulvestran...             2   \n",
       "18  [{'ado-trastuzumab emtansine'}, {'trastuzumab'...             1   \n",
       "19  [{'sacituzumab govitecan'}, {'trastuzumab deru...             1   \n",
       "20                                  [{'erdafitinib'}]             1   \n",
       "\n",
       "    missing_cnt  ...                               RAGLLM_full_output_0  \\\n",
       "0             0  ...  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "1             0  ...  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "2             0  ...  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "3             2  ...  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "4             0  ...  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "5             0  ...  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "6             0  ...  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "7             0  ...  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "8             0  ...  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "9             0  ...  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "10            0  ...  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "11            0  ...  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "12            0  ...  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "13            0  ...  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "14            0  ...  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "15            0  ...  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "16            0  ...  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "17            1  ...  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "18           10  ...  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "19            1  ...  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "20            0  ...  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "\n",
       "                                 RAGLLM_full_output_1  \\\n",
       "0   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "1   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "2   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "3   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "4   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "5   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "6   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "7   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "8   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "9   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "10  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "11  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "12  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "13  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "14  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "15  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "16  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "17  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "18  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "19  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "20  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "\n",
       "                                 RAGLLM_full_output_2  \\\n",
       "0   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "1   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "2   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "3   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "4   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "5   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "6   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "7   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "8   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "9   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "10  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "11  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "12  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "13  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "14  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "15  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "16  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "17  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "18  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "19  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "20  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "\n",
       "                                 RAGLLM_full_output_3  \\\n",
       "0   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "1   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "2   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "3   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "4   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "5   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "6   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "7   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "8   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "9   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "10  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "11  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "12  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "13  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "14  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "15  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "16  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "17  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "18  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "19  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "20  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "\n",
       "                                 RAGLLM_full_output_4  \\\n",
       "0   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "1   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "2   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "3   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "4   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "5   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "6   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "7   {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "8   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "9   {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "10  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "11  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "12  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "13  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "14  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "15  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "16  {\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No d...   \n",
       "17  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "18  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "19  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "20  {\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\...   \n",
       "\n",
       "                                RAGLLM_input_prompt_0  \\\n",
       "0   \\n    Context information is below.\\n    -----...   \n",
       "1   \\n    Context information is below.\\n    -----...   \n",
       "2   \\n    Context information is below.\\n    -----...   \n",
       "3   \\n    Context information is below.\\n    -----...   \n",
       "4   \\n    Context information is below.\\n    -----...   \n",
       "5   \\n    Context information is below.\\n    -----...   \n",
       "6   \\n    Context information is below.\\n    -----...   \n",
       "7   \\n    Context information is below.\\n    -----...   \n",
       "8   \\n    Context information is below.\\n    -----...   \n",
       "9   \\n    Context information is below.\\n    -----...   \n",
       "10  \\n    Context information is below.\\n    -----...   \n",
       "11  \\n    Context information is below.\\n    -----...   \n",
       "12  \\n    Context information is below.\\n    -----...   \n",
       "13  \\n    Context information is below.\\n    -----...   \n",
       "14  \\n    Context information is below.\\n    -----...   \n",
       "15  \\n    Context information is below.\\n    -----...   \n",
       "16  \\n    Context information is below.\\n    -----...   \n",
       "17  \\n    Context information is below.\\n    -----...   \n",
       "18  \\n    Context information is below.\\n    -----...   \n",
       "19  \\n    Context information is below.\\n    -----...   \n",
       "20  \\n    Context information is below.\\n    -----...   \n",
       "\n",
       "                                RAGLLM_input_prompt_1  \\\n",
       "0   \\n    Context information is below.\\n    -----...   \n",
       "1   \\n    Context information is below.\\n    -----...   \n",
       "2   \\n    Context information is below.\\n    -----...   \n",
       "3   \\n    Context information is below.\\n    -----...   \n",
       "4   \\n    Context information is below.\\n    -----...   \n",
       "5   \\n    Context information is below.\\n    -----...   \n",
       "6   \\n    Context information is below.\\n    -----...   \n",
       "7   \\n    Context information is below.\\n    -----...   \n",
       "8   \\n    Context information is below.\\n    -----...   \n",
       "9   \\n    Context information is below.\\n    -----...   \n",
       "10  \\n    Context information is below.\\n    -----...   \n",
       "11  \\n    Context information is below.\\n    -----...   \n",
       "12  \\n    Context information is below.\\n    -----...   \n",
       "13  \\n    Context information is below.\\n    -----...   \n",
       "14  \\n    Context information is below.\\n    -----...   \n",
       "15  \\n    Context information is below.\\n    -----...   \n",
       "16  \\n    Context information is below.\\n    -----...   \n",
       "17  \\n    Context information is below.\\n    -----...   \n",
       "18  \\n    Context information is below.\\n    -----...   \n",
       "19  \\n    Context information is below.\\n    -----...   \n",
       "20  \\n    Context information is below.\\n    -----...   \n",
       "\n",
       "                                RAGLLM_input_prompt_2  \\\n",
       "0   \\n    Context information is below.\\n    -----...   \n",
       "1   \\n    Context information is below.\\n    -----...   \n",
       "2   \\n    Context information is below.\\n    -----...   \n",
       "3   \\n    Context information is below.\\n    -----...   \n",
       "4   \\n    Context information is below.\\n    -----...   \n",
       "5   \\n    Context information is below.\\n    -----...   \n",
       "6   \\n    Context information is below.\\n    -----...   \n",
       "7   \\n    Context information is below.\\n    -----...   \n",
       "8   \\n    Context information is below.\\n    -----...   \n",
       "9   \\n    Context information is below.\\n    -----...   \n",
       "10  \\n    Context information is below.\\n    -----...   \n",
       "11  \\n    Context information is below.\\n    -----...   \n",
       "12  \\n    Context information is below.\\n    -----...   \n",
       "13  \\n    Context information is below.\\n    -----...   \n",
       "14  \\n    Context information is below.\\n    -----...   \n",
       "15  \\n    Context information is below.\\n    -----...   \n",
       "16  \\n    Context information is below.\\n    -----...   \n",
       "17  \\n    Context information is below.\\n    -----...   \n",
       "18  \\n    Context information is below.\\n    -----...   \n",
       "19  \\n    Context information is below.\\n    -----...   \n",
       "20  \\n    Context information is below.\\n    -----...   \n",
       "\n",
       "                                RAGLLM_input_prompt_3  \\\n",
       "0   \\n    Context information is below.\\n    -----...   \n",
       "1   \\n    Context information is below.\\n    -----...   \n",
       "2   \\n    Context information is below.\\n    -----...   \n",
       "3   \\n    Context information is below.\\n    -----...   \n",
       "4   \\n    Context information is below.\\n    -----...   \n",
       "5   \\n    Context information is below.\\n    -----...   \n",
       "6   \\n    Context information is below.\\n    -----...   \n",
       "7   \\n    Context information is below.\\n    -----...   \n",
       "8   \\n    Context information is below.\\n    -----...   \n",
       "9   \\n    Context information is below.\\n    -----...   \n",
       "10  \\n    Context information is below.\\n    -----...   \n",
       "11  \\n    Context information is below.\\n    -----...   \n",
       "12  \\n    Context information is below.\\n    -----...   \n",
       "13  \\n    Context information is below.\\n    -----...   \n",
       "14  \\n    Context information is below.\\n    -----...   \n",
       "15  \\n    Context information is below.\\n    -----...   \n",
       "16  \\n    Context information is below.\\n    -----...   \n",
       "17  \\n    Context information is below.\\n    -----...   \n",
       "18  \\n    Context information is below.\\n    -----...   \n",
       "19  \\n    Context information is below.\\n    -----...   \n",
       "20  \\n    Context information is below.\\n    -----...   \n",
       "\n",
       "                                RAGLLM_input_prompt_4  \n",
       "0   \\n    Context information is below.\\n    -----...  \n",
       "1   \\n    Context information is below.\\n    -----...  \n",
       "2   \\n    Context information is below.\\n    -----...  \n",
       "3   \\n    Context information is below.\\n    -----...  \n",
       "4   \\n    Context information is below.\\n    -----...  \n",
       "5   \\n    Context information is below.\\n    -----...  \n",
       "6   \\n    Context information is below.\\n    -----...  \n",
       "7   \\n    Context information is below.\\n    -----...  \n",
       "8   \\n    Context information is below.\\n    -----...  \n",
       "9   \\n    Context information is below.\\n    -----...  \n",
       "10  \\n    Context information is below.\\n    -----...  \n",
       "11  \\n    Context information is below.\\n    -----...  \n",
       "12  \\n    Context information is below.\\n    -----...  \n",
       "13  \\n    Context information is below.\\n    -----...  \n",
       "14  \\n    Context information is below.\\n    -----...  \n",
       "15  \\n    Context information is below.\\n    -----...  \n",
       "16  \\n    Context information is below.\\n    -----...  \n",
       "17  \\n    Context information is below.\\n    -----...  \n",
       "18  \\n    Context information is below.\\n    -----...  \n",
       "19  \\n    Context information is below.\\n    -----...  \n",
       "20  \\n    Context information is below.\\n    -----...  \n",
       "\n",
       "[21 rows x 27 columns]"
      ]
     },
     "execution_count": 157,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "real_supp_df = pd.concat([real_rag_res_cnt_df_5, drug_output_df, full_output_df, input_df], axis=1)\n",
    "real_supp_df\n",
    "\n",
    "# real_supp_df.to_csv(\"./real_supp_df.csv\", index=False)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.14"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
